for Journals by Title or ISSN
for Articles by Keywords
help

Publisher: John Wiley and Sons   (Total: 1582 journals)

 A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

        1 2 3 4 5 6 7 8 | Last   [Sort by number of followers]   [Restore default list]

Showing 1 - 200 of 1583 Journals sorted alphabetically
Abacus     Hybrid Journal   (Followers: 11, SJR: 0.48, h-index: 22)
About Campus     Hybrid Journal   (Followers: 5)
Academic Emergency Medicine     Hybrid Journal   (Followers: 53, SJR: 1.385, h-index: 91)
Accounting & Finance     Hybrid Journal   (Followers: 43, SJR: 0.547, h-index: 30)
ACEP NOW     Free  
Acta Anaesthesiologica Scandinavica     Hybrid Journal   (Followers: 50, SJR: 1.02, h-index: 88)
Acta Archaeologica     Hybrid Journal   (Followers: 132, SJR: 0.101, h-index: 9)
Acta Geologica Sinica (English Edition)     Hybrid Journal   (Followers: 3, SJR: 0.552, h-index: 41)
Acta Neurologica Scandinavica     Hybrid Journal   (Followers: 5, SJR: 1.203, h-index: 74)
Acta Obstetricia et Gynecologica Scandinavica     Hybrid Journal   (Followers: 15, SJR: 1.197, h-index: 81)
Acta Ophthalmologica     Hybrid Journal   (Followers: 5, SJR: 0.112, h-index: 1)
Acta Paediatrica     Hybrid Journal   (Followers: 54, SJR: 0.794, h-index: 88)
Acta Physiologica     Hybrid Journal   (Followers: 7, SJR: 1.69, h-index: 88)
Acta Polymerica     Hybrid Journal   (Followers: 9)
Acta Psychiatrica Scandinavica     Hybrid Journal   (Followers: 35, SJR: 2.518, h-index: 113)
Acta Zoologica     Hybrid Journal   (Followers: 5, SJR: 0.459, h-index: 29)
Acute Medicine & Surgery     Hybrid Journal   (Followers: 2)
Addiction     Hybrid Journal   (Followers: 32, SJR: 2.086, h-index: 143)
Addiction Biology     Hybrid Journal   (Followers: 12, SJR: 2.091, h-index: 57)
Adultspan J.     Hybrid Journal   (SJR: 0.127, h-index: 4)
Advanced Energy Materials     Hybrid Journal   (Followers: 24, SJR: 6.411, h-index: 86)
Advanced Engineering Materials     Hybrid Journal   (Followers: 25, SJR: 0.81, h-index: 81)
Advanced Functional Materials     Hybrid Journal   (Followers: 47, SJR: 5.21, h-index: 203)
Advanced Healthcare Materials     Hybrid Journal   (Followers: 13, SJR: 0.232, h-index: 7)
Advanced Materials     Hybrid Journal   (Followers: 246, SJR: 9.021, h-index: 345)
Advanced Materials Interfaces     Hybrid Journal   (Followers: 6, SJR: 1.177, h-index: 10)
Advanced Optical Materials     Hybrid Journal   (Followers: 4, SJR: 2.488, h-index: 21)
Advanced Science     Open Access   (Followers: 4)
Advanced Synthesis & Catalysis     Hybrid Journal   (Followers: 17, SJR: 2.729, h-index: 121)
Advances in Polymer Technology     Hybrid Journal   (Followers: 13, SJR: 0.344, h-index: 31)
Africa Confidential     Hybrid Journal   (Followers: 19)
Africa Research Bulletin: Economic, Financial and Technical Series     Hybrid Journal   (Followers: 12)
Africa Research Bulletin: Political, Social and Cultural Series     Hybrid Journal   (Followers: 9)
African Development Review     Hybrid Journal   (Followers: 33, SJR: 0.275, h-index: 17)
African J. of Ecology     Hybrid Journal   (Followers: 14, SJR: 0.477, h-index: 39)
Aggressive Behavior     Hybrid Journal   (Followers: 15, SJR: 1.391, h-index: 66)
Aging Cell     Open Access   (Followers: 9, SJR: 4.374, h-index: 95)
Agribusiness : an Intl. J.     Hybrid Journal   (Followers: 6, SJR: 0.627, h-index: 14)
Agricultural and Forest Entomology     Hybrid Journal   (Followers: 14, SJR: 0.925, h-index: 43)
Agricultural Economics     Hybrid Journal   (Followers: 44, SJR: 1.099, h-index: 51)
AIChE J.     Hybrid Journal   (Followers: 28, SJR: 1.122, h-index: 120)
Alcoholism and Drug Abuse Weekly     Hybrid Journal   (Followers: 7)
Alcoholism Clinical and Experimental Research     Hybrid Journal   (Followers: 7, SJR: 1.416, h-index: 125)
Alimentary Pharmacology & Therapeutics     Hybrid Journal   (Followers: 33, SJR: 2.833, h-index: 138)
Alimentary Pharmacology & Therapeutics Symposium Series     Hybrid Journal   (Followers: 3)
Allergy     Hybrid Journal   (Followers: 49, SJR: 3.048, h-index: 129)
Alternatives to the High Cost of Litigation     Hybrid Journal   (Followers: 3)
American Anthropologist     Hybrid Journal   (Followers: 127, SJR: 0.951, h-index: 61)
American Business Law J.     Hybrid Journal   (Followers: 24, SJR: 0.205, h-index: 17)
American Ethnologist     Hybrid Journal   (Followers: 89, SJR: 2.325, h-index: 51)
American J. of Economics and Sociology     Hybrid Journal   (Followers: 28, SJR: 0.211, h-index: 26)
American J. of Hematology     Hybrid Journal   (Followers: 30, SJR: 1.761, h-index: 77)
American J. of Human Biology     Hybrid Journal   (Followers: 12, SJR: 1.018, h-index: 58)
American J. of Industrial Medicine     Hybrid Journal   (Followers: 16, SJR: 0.993, h-index: 85)
American J. of Medical Genetics Part A     Hybrid Journal   (Followers: 15, SJR: 1.115, h-index: 61)
American J. of Medical Genetics Part B: Neuropsychiatric Genetics     Hybrid Journal   (Followers: 3, SJR: 1.771, h-index: 107)
American J. of Medical Genetics Part C: Seminars in Medical Genetics     Partially Free   (Followers: 5, SJR: 2.315, h-index: 79)
American J. of Orthopsychiatry     Hybrid Journal   (Followers: 4, SJR: 0.756, h-index: 69)
American J. of Physical Anthropology     Hybrid Journal   (Followers: 35, SJR: 1.41, h-index: 88)
American J. of Political Science     Hybrid Journal   (Followers: 235, SJR: 5.101, h-index: 114)
American J. of Primatology     Hybrid Journal   (Followers: 14, SJR: 1.197, h-index: 63)
American J. of Reproductive Immunology     Hybrid Journal   (Followers: 3, SJR: 1.347, h-index: 75)
American J. of Transplantation     Hybrid Journal   (Followers: 15, SJR: 2.792, h-index: 140)
American J. on Addictions     Hybrid Journal   (Followers: 9, SJR: 0.843, h-index: 57)
Anaesthesia     Hybrid Journal   (Followers: 115, SJR: 1.404, h-index: 88)
Analyses of Social Issues and Public Policy     Hybrid Journal   (Followers: 11, SJR: 0.397, h-index: 18)
Analytic Philosophy     Hybrid Journal   (Followers: 15)
Anatomia, Histologia, Embryologia: J. of Veterinary Medicine Series C     Hybrid Journal   (Followers: 3, SJR: 0.295, h-index: 27)
Anatomical Sciences Education     Hybrid Journal   (Followers: 1, SJR: 0.633, h-index: 24)
Andrologia     Hybrid Journal   (Followers: 2, SJR: 0.528, h-index: 45)
Andrology     Hybrid Journal   (Followers: 2, SJR: 0.979, h-index: 14)
Angewandte Chemie     Hybrid Journal   (Followers: 153)
Angewandte Chemie Intl. Edition     Hybrid Journal   (Followers: 203, SJR: 6.229, h-index: 397)
Animal Conservation     Hybrid Journal   (Followers: 34, SJR: 1.576, h-index: 62)
Animal Genetics     Hybrid Journal   (Followers: 8, SJR: 0.957, h-index: 67)
Animal Science J.     Hybrid Journal   (Followers: 5, SJR: 0.569, h-index: 24)
Annalen der Physik     Hybrid Journal   (Followers: 5, SJR: 1.46, h-index: 40)
Annals of Anthropological Practice     Partially Free   (Followers: 2, SJR: 0.187, h-index: 5)
Annals of Applied Biology     Hybrid Journal   (Followers: 8, SJR: 0.816, h-index: 56)
Annals of Clinical and Translational Neurology     Open Access   (Followers: 1)
Annals of Human Genetics     Hybrid Journal   (Followers: 9, SJR: 1.191, h-index: 67)
Annals of Neurology     Hybrid Journal   (Followers: 42, SJR: 5.584, h-index: 241)
Annals of Noninvasive Electrocardiology     Hybrid Journal   (Followers: 2, SJR: 0.531, h-index: 38)
Annals of Public and Cooperative Economics     Hybrid Journal   (Followers: 9, SJR: 0.336, h-index: 23)
Annals of the New York Academy of Sciences     Hybrid Journal   (Followers: 5, SJR: 2.389, h-index: 189)
Annual Bulletin of Historical Literature     Hybrid Journal   (Followers: 12)
Annual Review of Information Science and Technology     Hybrid Journal   (Followers: 14)
Anthropology & Education Quarterly     Hybrid Journal   (Followers: 24, SJR: 0.72, h-index: 31)
Anthropology & Humanism     Hybrid Journal   (Followers: 16, SJR: 0.137, h-index: 3)
Anthropology News     Hybrid Journal   (Followers: 14)
Anthropology of Consciousness     Hybrid Journal   (Followers: 11, SJR: 0.172, h-index: 5)
Anthropology of Work Review     Hybrid Journal   (Followers: 11, SJR: 0.256, h-index: 5)
Anthropology Today     Hybrid Journal   (Followers: 92, SJR: 0.545, h-index: 15)
Antipode     Hybrid Journal   (Followers: 45, SJR: 2.212, h-index: 69)
Anz J. of Surgery     Hybrid Journal   (Followers: 6, SJR: 0.432, h-index: 59)
Anzeiger für Schädlingskunde     Hybrid Journal   (Followers: 1)
Apmis     Hybrid Journal   (Followers: 1, SJR: 0.855, h-index: 73)
Applied Cognitive Psychology     Hybrid Journal   (Followers: 66, SJR: 0.754, h-index: 69)
Applied Organometallic Chemistry     Hybrid Journal   (Followers: 6, SJR: 0.632, h-index: 58)
Applied Psychology     Hybrid Journal   (Followers: 128, SJR: 1.023, h-index: 64)
Applied Psychology: Health and Well-Being     Hybrid Journal   (Followers: 47, SJR: 0.868, h-index: 13)
Applied Stochastic Models in Business and Industry     Hybrid Journal   (Followers: 5, SJR: 0.613, h-index: 24)
Aquaculture Nutrition     Hybrid Journal   (Followers: 13, SJR: 1.025, h-index: 55)
Aquaculture Research     Hybrid Journal   (Followers: 31, SJR: 0.807, h-index: 60)
Aquatic Conservation Marine and Freshwater Ecosystems     Hybrid Journal   (Followers: 34, SJR: 1.047, h-index: 57)
Arabian Archaeology and Epigraphy     Hybrid Journal   (Followers: 11, SJR: 0.453, h-index: 11)
Archaeological Prospection     Hybrid Journal   (Followers: 12, SJR: 0.922, h-index: 21)
Archaeology in Oceania     Hybrid Journal   (Followers: 13, SJR: 0.745, h-index: 18)
Archaeometry     Hybrid Journal   (Followers: 27, SJR: 0.809, h-index: 48)
Archeological Papers of The American Anthropological Association     Hybrid Journal   (Followers: 14, SJR: 0.156, h-index: 2)
Architectural Design     Hybrid Journal   (Followers: 24, SJR: 0.261, h-index: 9)
Archiv der Pharmazie     Hybrid Journal   (Followers: 4, SJR: 0.628, h-index: 43)
Archives of Drug Information     Hybrid Journal   (Followers: 4)
Archives of Insect Biochemistry and Physiology     Hybrid Journal   (SJR: 0.768, h-index: 54)
Area     Hybrid Journal   (Followers: 12, SJR: 0.938, h-index: 57)
Art History     Hybrid Journal   (Followers: 203, SJR: 0.153, h-index: 13)
Arthritis & Rheumatology     Hybrid Journal   (Followers: 48, SJR: 1.984, h-index: 20)
Arthritis Care & Research     Hybrid Journal   (Followers: 27, SJR: 2.256, h-index: 114)
Artificial Organs     Hybrid Journal   (Followers: 1, SJR: 0.872, h-index: 60)
ASHE Higher Education Reports     Hybrid Journal   (Followers: 13)
Asia & the Pacific Policy Studies     Open Access   (Followers: 15)
Asia Pacific J. of Human Resources     Hybrid Journal   (Followers: 316, SJR: 0.494, h-index: 19)
Asia Pacific Viewpoint     Hybrid Journal   (SJR: 0.616, h-index: 26)
Asia-Pacific J. of Chemical Engineering     Hybrid Journal   (Followers: 7, SJR: 0.345, h-index: 20)
Asia-pacific J. of Clinical Oncology     Hybrid Journal   (Followers: 6, SJR: 0.554, h-index: 14)
Asia-Pacific J. of Financial Studies     Hybrid Journal   (SJR: 0.241, h-index: 7)
Asia-Pacific Psychiatry     Hybrid Journal   (Followers: 3, SJR: 0.377, h-index: 7)
Asian Economic J.     Hybrid Journal   (Followers: 8, SJR: 0.234, h-index: 21)
Asian Economic Policy Review     Hybrid Journal   (Followers: 3, SJR: 0.196, h-index: 12)
Asian J. of Control     Hybrid Journal   (SJR: 0.862, h-index: 34)
Asian J. of Endoscopic Surgery     Hybrid Journal   (SJR: 0.394, h-index: 7)
Asian J. of Organic Chemistry     Hybrid Journal   (Followers: 4, SJR: 1.443, h-index: 19)
Asian J. of Social Psychology     Hybrid Journal   (Followers: 5, SJR: 0.665, h-index: 37)
Asian Politics and Policy     Hybrid Journal   (Followers: 13, SJR: 0.207, h-index: 7)
Asian Social Work and Policy Review     Hybrid Journal   (Followers: 5, SJR: 0.318, h-index: 5)
Asian-pacific Economic Literature     Hybrid Journal   (Followers: 5, SJR: 0.168, h-index: 15)
Assessment Update     Hybrid Journal   (Followers: 4)
Astronomische Nachrichten     Hybrid Journal   (Followers: 2, SJR: 0.701, h-index: 40)
Atmospheric Science Letters     Open Access   (Followers: 29, SJR: 1.332, h-index: 27)
Austral Ecology     Hybrid Journal   (Followers: 12, SJR: 1.095, h-index: 66)
Austral Entomology     Hybrid Journal   (Followers: 10, SJR: 0.524, h-index: 28)
Australasian J. of Dermatology     Hybrid Journal   (Followers: 7, SJR: 0.714, h-index: 40)
Australasian J. On Ageing     Hybrid Journal   (Followers: 7, SJR: 0.39, h-index: 22)
Australian & New Zealand J. of Statistics     Hybrid Journal   (Followers: 13, SJR: 0.275, h-index: 28)
Australian Accounting Review     Hybrid Journal   (Followers: 3, SJR: 0.709, h-index: 14)
Australian and New Zealand J. of Family Therapy (ANZJFT)     Hybrid Journal   (Followers: 3, SJR: 0.382, h-index: 12)
Australian and New Zealand J. of Obstetrics and Gynaecology     Hybrid Journal   (Followers: 42, SJR: 0.814, h-index: 49)
Australian and New Zealand J. of Public Health     Hybrid Journal   (Followers: 11, SJR: 0.82, h-index: 62)
Australian Dental J.     Hybrid Journal   (Followers: 6, SJR: 0.482, h-index: 46)
Australian Economic History Review     Hybrid Journal   (Followers: 4, SJR: 0.171, h-index: 12)
Australian Economic Papers     Hybrid Journal   (Followers: 21, SJR: 0.23, h-index: 9)
Australian Economic Review     Hybrid Journal   (Followers: 6, SJR: 0.357, h-index: 21)
Australian Endodontic J.     Hybrid Journal   (Followers: 3, SJR: 0.513, h-index: 24)
Australian J. of Agricultural and Resource Economics     Hybrid Journal   (Followers: 3, SJR: 0.765, h-index: 36)
Australian J. of Grape and Wine Research     Hybrid Journal   (Followers: 5, SJR: 0.879, h-index: 56)
Australian J. of Politics & History     Hybrid Journal   (Followers: 13, SJR: 0.203, h-index: 14)
Australian J. of Psychology     Hybrid Journal   (Followers: 16, SJR: 0.384, h-index: 30)
Australian J. of Public Administration     Hybrid Journal   (Followers: 381, SJR: 0.418, h-index: 29)
Australian J. of Rural Health     Hybrid Journal   (Followers: 4, SJR: 0.43, h-index: 34)
Australian Occupational Therapy J.     Hybrid Journal   (Followers: 64, SJR: 0.59, h-index: 29)
Australian Psychologist     Hybrid Journal   (Followers: 11, SJR: 0.331, h-index: 31)
Australian Veterinary J.     Hybrid Journal   (Followers: 19, SJR: 0.459, h-index: 45)
Autism Research     Hybrid Journal   (Followers: 31, SJR: 2.126, h-index: 39)
Autonomic & Autacoid Pharmacology     Hybrid Journal   (SJR: 0.371, h-index: 29)
Banks in Insurance Report     Hybrid Journal   (Followers: 1)
Basic & Clinical Pharmacology & Toxicology     Hybrid Journal   (Followers: 9, SJR: 0.539, h-index: 70)
Basic and Applied Pathology     Open Access   (Followers: 2, SJR: 0.113, h-index: 4)
Basin Research     Hybrid Journal   (Followers: 3, SJR: 1.54, h-index: 60)
Bauphysik     Hybrid Journal   (Followers: 2, SJR: 0.194, h-index: 5)
Bauregelliste A, Bauregelliste B Und Liste C     Hybrid Journal  
Bautechnik     Hybrid Journal   (Followers: 1, SJR: 0.321, h-index: 11)
Behavioral Interventions     Hybrid Journal   (Followers: 7, SJR: 0.297, h-index: 23)
Behavioral Sciences & the Law     Hybrid Journal   (Followers: 21, SJR: 0.736, h-index: 57)
Berichte Zur Wissenschaftsgeschichte     Hybrid Journal   (Followers: 9, SJR: 0.11, h-index: 5)
Beton- und Stahlbetonbau     Hybrid Journal   (Followers: 2, SJR: 0.493, h-index: 14)
Biochemistry and Molecular Biology Education     Hybrid Journal   (Followers: 6, SJR: 0.311, h-index: 26)
Bioelectromagnetics     Hybrid Journal   (Followers: 1, SJR: 0.568, h-index: 64)
Bioengineering & Translational Medicine     Open Access  
BioEssays     Hybrid Journal   (Followers: 10, SJR: 3.104, h-index: 155)
Bioethics     Hybrid Journal   (Followers: 14, SJR: 0.686, h-index: 39)
Biofuels, Bioproducts and Biorefining     Hybrid Journal   (Followers: 1, SJR: 1.725, h-index: 56)
Biological J. of the Linnean Society     Hybrid Journal   (Followers: 14, SJR: 1.172, h-index: 90)
Biological Reviews     Hybrid Journal   (Followers: 2, SJR: 6.469, h-index: 114)
Biologie in Unserer Zeit (Biuz)     Hybrid Journal   (Followers: 44, SJR: 0.12, h-index: 1)
Biology of the Cell     Full-text available via subscription   (Followers: 9, SJR: 1.812, h-index: 69)
Biomedical Chromatography     Hybrid Journal   (Followers: 6, SJR: 0.572, h-index: 49)
Biometrical J.     Hybrid Journal   (Followers: 5, SJR: 0.784, h-index: 44)
Biometrics     Hybrid Journal   (Followers: 37, SJR: 1.906, h-index: 96)
Biopharmaceutics and Drug Disposition     Hybrid Journal   (Followers: 10, SJR: 0.715, h-index: 44)
Biopolymers     Hybrid Journal   (Followers: 18, SJR: 1.199, h-index: 104)
Biotechnology and Applied Biochemistry     Hybrid Journal   (Followers: 45, SJR: 0.415, h-index: 55)
Biotechnology and Bioengineering     Hybrid Journal   (Followers: 134, SJR: 1.633, h-index: 146)
Biotechnology J.     Hybrid Journal   (Followers: 13, SJR: 1.185, h-index: 51)
Biotechnology Progress     Hybrid Journal   (Followers: 39, SJR: 0.736, h-index: 101)
Biotropica     Hybrid Journal   (Followers: 17, SJR: 1.374, h-index: 71)
Bipolar Disorders     Hybrid Journal   (Followers: 10, SJR: 2.592, h-index: 100)
Birth     Hybrid Journal   (Followers: 33, SJR: 0.763, h-index: 64)
Birth Defects Research Part A : Clinical and Molecular Teratology     Hybrid Journal   (Followers: 2, SJR: 0.727, h-index: 77)
Birth Defects Research Part B: Developmental and Reproductive Toxicology     Hybrid Journal   (Followers: 5, SJR: 0.468, h-index: 47)
Birth Defects Research Part C : Embryo Today : Reviews     Hybrid Journal   (SJR: 1.513, h-index: 55)

        1 2 3 4 5 6 7 8 | Last   [Sort by number of followers]   [Restore default list]

Journal Cover Analyses of Social Issues and Public Policy
  [SJR: 0.397]   [H-I: 18]   [11 followers]  Follow
    
   Hybrid Journal Hybrid journal (It can contain Open Access articles)
   ISSN (Print) 1529-7489 - ISSN (Online) 1530-2415
   Published by John Wiley and Sons Homepage  [1582 journals]
  • When Cooperation and Compromise Fail: Distrusting and Denigrating the
           Moral Character of Those Who Disagree
    • Authors: Jamie S. Hughes
      Abstract: People tend to view adversaries with dissimilar opinions as irrational, biased, and negatively motivated. However, when adversaries show honest attempts to compromise evaluations should become more positive. Unfortunately, the evidence presented here does not support this idea. Across five studies using different attitudinal issues perceivers believed dissimilar attitude targets were negatively motivated, untrustworthy, and less moral compared to similar attitude targets. Further, moral character judgments mediated the relationship between attitude target and trust. Fortunately, the strong association between motives and morality provided an opportunity to intervene. Those explicitly told that an attitude target held positive rather than negative long-term motives evaluated those with dissimilar and similar attitudes positively. Discussion focuses on the importance of these findings for theory and public policy.
      PubDate: 2017-02-24T07:25:39.885464-05:
      DOI: 10.1111/asap.12131
       
  • Racial Resentment, Hurricane Sandy, and the Spillover of Racial Attitudes
           into Evaluations of Government Organizations
    • Authors: Geoffrey Sheagley; Philip Chen, Christina Farhart
      Abstract: This study explores the relationship between individuals’ racial attitudes, exposure to information cuing them to think about President Obama, and evaluations of the government's response to Hurricane Sandy. Using a split ballot experiment embedded in a large internet panel fielded during the 2012 presidential election, we show that respondents’ evaluations of President Obama's response to Hurricane Sandy were based on their racial attitudes. We next examined the possibility for racial attitudes to “spill over” into how people evaluate governmental institutions and organizations associated with President Obama. We found evidence that respondents who were cued to think about President Obama and were impacted by Hurricane Sandy were more likely to base their evaluations of the Federal Emergency Management Agency's response to the disaster on their racial attitudes. In short, linking President Obama to Hurricane Sandy led people to ground their evaluations of an organization tasked with coordinating the response to Hurricane Sandy in their racial attitudes. Our research suggests that racial attitudes are important predictors of how individuals perceive President Obama's effectiveness as well as the efficacy of related government organizations.
      PubDate: 2017-02-23T01:25:28.373037-05:
      DOI: 10.1111/asap.12130
       
  • Shift in disparities in hepatitis C treatment from interferon to DAA era:
           A population-based cohort study
    • Authors: N. Z. Janjua; N. Islam, J. Wong, E. M. Yoshida, A. Ramji, H. Samji, Z. A. Butt, M. Chong, D. Cook, M. Alvarez, M. Darvishian, M. Tyndall, M. Krajden
      Abstract: We evaluated the shift in the characteristics of people who received interferon-based hepatitis C virus (HCV) treatments and those who received recently introduced direct-acting antivirals (DAAs) in British Columbia (BC), Canada. The BC Hepatitis Testers Cohort includes 1.5 million individuals tested for HCV or HIV, or reported cases of hepatitis B and active tuberculosis in BC from 1990 to 2013 linked to medical visits, hospitalization, cancer, prescription drugs and mortality data. This analysis included all patients who filled at least one prescription for HCV treatment until 31 July 2015. HCV treatments were classified as older interferon-based treatments including pegylated interferon/ribavirin (PegIFN/RBV) with/without boceprevir or telaprevir, DAAs with RBV or PegIFN/RBV, and newer interferon-free DAAs. Of 11 886 people treated for HCV between 2000 and 2015, 1164 (9.8%) received interferon-free DAAs (ledipasvir/sofosbuvir: n=1075; 92.4%), while 452 (3.8%) received a combination of DAAs and RBV or PegIFN/RBV. Compared to those receiving interferon-based treatment, people with HIV co-infection (adjusted odds ratio [aOR]: 2.96, 95% CI: 2.31-3.81), cirrhosis (aOR: 1.77, 95% CI: 1.45-2.15), decompensated cirrhosis (aOR: 1.72, 95% CI: 1.31-2.28), diabetes (aOR: 1.30, 95% CI: 1.10-1.54), a history of injection drug use (aOR: 1.34, 95% CI: 1.09-1.65) and opioid substitution therapy (aOR: 1.30, 95% CI: 1.01-1.67) were more likely to receive interferon-free DAAs. Socio-economically marginalized individuals were significantly less likely (most deprived vs most privileged: aOR: 0.71, 95% CI: 0.58-0.87) to receive DAAs. In conclusion, there is a shift in prescription of new HCV treatments to previously excluded groups (eg HIV-co-infected), although gaps remain for the socio-economically marginalized populations.
      PubDate: 2017-02-20T00:30:28.050408-05:
      DOI: 10.1111/jvh.12684
       
  • Improving access to health care for chronic hepatitis B among migrant
           Chinese populations: A systematic mixed methods review of barriers and
           enablers
    • Authors: A. Vedio; E. Z. H. Liu, A. C. K. Lee, S. Salway
      Abstract: Migrant Chinese populations in Western countries have a high prevalence of chronic hepatitis B but often experience poor access to health care and late diagnosis. This systematic review aimed to identify obstacles and supports to timely and appropriate health service use among these populations. Systematic searches resulted in 48 relevant studies published between 1996 and 2015. Data extraction and synthesis were informed by models of healthcare access that highlight the interplay of patient, provider and health system factors. There was strong consistent evidence of low levels of knowledge among patients and community members; but interventions that were primarily focused on increasing knowledge had only modest positive effects on testing and/or vaccination. There was strong consistent evidence that Chinese migrants tend to misunderstand the need for health care for hepatitis B and have low satisfaction with services. Stigma was consistently associated with hepatitis B, and there was weak but consistent evidence of stigma acting as a barrier to care. However, available evidence on the effects of providing culturally appropriate services for hepatitis B on increasing uptake is limited. There was strong consistent evidence that health professionals miss opportunities for testing and vaccination. Practitioner education interventions may be important, but evidence of effectiveness is limited. A simple prompt in patient records for primary care physicians improved the uptake of testing, and a dedicated service increased targeted vaccination coverage for newborns. Further development and more rigorous evaluation of more holistic approaches that address patient, provider and system obstacles are needed.
      PubDate: 2017-02-20T00:25:43.492841-05:
      DOI: 10.1111/jvh.12673
       
  • Predictors of liver histological changes and a sustained virological
           response to peginterferon among chronic hepatitis B e antigen-positive
           patients with normal or minimally elevated alanine aminotransferase levels
           
    • Authors: J. Chen; C. R. Xu, M. Xi, W. W. Hu, Z. H. Tang, G. Q. Zang
      Abstract: A proportion of chronic hepatitis B patients with normal or only minimally elevated alanine aminotransferase (ALT) levels display significant histologic changes and would benefit from antiviral therapy. We aim to evaluate the histologic abnormalities seen in these patients and then determine which of them would most likely respond to peginterferon therapy. One hundred and thirteen hepatitis B e antigen (HBeAg)-positive patients with a normal or minimally elevated ALT level and moderate-to-severe histologic changes in their liver tissue were selected to receive peginterferon monotherapy and participate in a follow-up analysis. A multiple logistic regression analysis indicated that increasing age (P=.049) and lower hepatitis B virus (HBV) DNA levels (P=.038) were associated with significant histological abnormalities in patients with a normal or minimally elevated ALT. Our predictive model which incorporated HBeAg testing at treatment week 12 combined with hepatitis B surface antigen (HBsAg) testing at treatment week 24 was able to identify which patients with a normal ALT level would achieve a sustained virological response (SVR) (positive predictive value [PPV]: 66.7%, negative predictive value [NPV]: 90.0%). Lower HBsAg and HBeAg levels at treatment week 24 were associated with a SVR in patients with a minimally elevated ALT level (PPV: 100.0%, NPV: 100.0%). A liver biopsy and antiviral therapy should be strongly considered when treating HBeAg-positive patients with a normal or minimally elevated ALT level, low HBV DNA level, and aged >35 years. On-treatment quantification of combined HBsAg and HBeAg test results may be useful for predicting a SVR to peginterferon monotherapy in these patients.
      PubDate: 2017-02-16T05:11:33.860978-05:
      DOI: 10.1111/jvh.12679
       
  • Long-term safety and efficacy of telbivudine in infants born to mothers
           treated during the second or third trimesters of pregnancy
    • Authors: G.-R. Han; H.-X. Jiang, C.-M. Wang, Y. Ding, G.-J. Wang, X. Yue, L. Zhou, W. Zhao
      Abstract: Telbivudine, an FDA pregnancy category B drug, has been found to reduce hepatitis B virus (HBV) perinatal transmission with no safety concerns in infants aged up to 1 year. This study evaluated the long-term efficacy and safety of telbivudine in 214 infants born to 210 pregnant women with chronic hepatitis B infection who were treated with telbivudine during pregnancy (weeks 20-32 of gestation). The infants were followed for up to 5 years after birth. The efficacy endpoint was the rate of perinatal transmission, which was established by HBsAg and HBV DNA levels at 7 and 12 months. Safety endpoints included head circumference, weight, height, congenital abnormality and hospitalization rates. In addition, the Denver Developmental Screening Test was performed in 92 randomly selected infants. None of the 214 infants born to these women were infected with HBV, and all had effective serum hepatitis B surface antibody (HBsAb) levels. Compared with Chinese standard values, there were few differences in the infants’ mean head circumference, weight, and height values. No birth defects were diagnosed, and the congenital abnormality rate was 0.934%. Serious adverse events requiring hospitalization occurred in 20 infants (9.35%). The qualified Denver Developmental Screening Test rate in 92 infants was 97.82%, which was comparable to a rate of 92% in normal Chinese children. Thus, treatment with telbivudine during the second or third trimesters of pregnancy safely blocked perinatal transmission of HBV. Infants born to telbivudine-treated mothers showed normal growth and development during long-term follow-up of up to 5 years.
      PubDate: 2017-02-14T05:31:26.848017-05:
      DOI: 10.1111/jvh.12670
       
  • Persistent neuropsychiatric impairment in HCV patients despite clearance
           of the virus?!
    • Authors: M. Dirks; H. Pflugrad, K. Haag, H. L. Tillmann, H. Wedemeyer, D. Arvanitis, H. Hecker, A. Tountopoulou, A. Goldbecker, H. Worthmann, K. Weissenborn
      Abstract: One of the most disabling symptoms of hepatitis C virus (HCV) infection is chronic fatigue. While this is accepted for HCV polymerase chain reaction (PCR)-positive patients, a relationship between HCV infection and chronic fatigue is questioned after successful virus eradication. As fatigue is a subjective criterion, we aimed to evaluate in addition mood alterations and cognitive function in HCV-exposed patients with only mild liver disease and to assess a) possible interrelationships between these factors and health-related quality of life and b) the impact of viremia and former interferon treatment. One hundred and fifty-nine anti-HCV-positive individuals without advanced liver disease answered health-related quality of life (HRQoL), fatigue and depression questionnaires and underwent a battery of attention and memory tests. Accompanying diseases which could distort the results of the study such as HIV co-infection or drug addiction were exclusion criteria. The patients were subdivided into four groups according to their viremia status and interferon treatment history. Patients' data were evaluated with respect to norms given in the respective test manuals and in addition compared to those of 33 age-matched healthy controls. Eighty-five per cent of the patients had chronic fatigue, 50-60% mild depression or anxiety, 45% memory deficits and 30% attention deficits, irrespective of their HCV viremia status or treatment history. HRQoL correlated negatively with chronic fatigue (P
      PubDate: 2017-02-09T03:31:19.748269-05:
      DOI: 10.1111/jvh.12674
       
  • Serum lincRNA-p21 as a potential biomarker of liver fibrosis in chronic
           hepatitis B patients
    • Authors: Fujun Yu; Guangyao Zhou, Kate Huang, XuFei Fan, Guojun Li, Bicheng Chen, Peihong Dong, Jianjian Zheng
      Abstract: Serum long non-coding RNAs (lncRNAs) are emerging as promising biomarkers for various human diseases. The aim of this study was to investigate the feasibility of using serum long intergenic non-coding RNA-p21 (lincRNA-p21) as a biomarker for chronic hepatitis B patients. Serum lincRNA-p21 levels were quantified using real-time PCR in 417 CHB patients and 363 healthy controls. The promoter methylation level of lincRNA-p21 was detected using bisulphite-sequencing analysis in primary hepatic stellate cells (HSCs). Sera from hepatitis B-infected patients contained lower levels of lincRNA-p21 than sera from healthy controls. Serum lincRNA-p21 levels negatively correlated with stages of liver fibrosis in infected patients. Receiver operating characteristic (ROC) curve analyses suggested that serum lincRNA-p21 had a significant diagnostic value for liver fibrosis in these patients. It yielded an area under the curve of ROC of 0.854 with 100% sensitivity and 70% specificity in discriminating liver fibrosis from healthy controls. There was additionally a negative correlation between serum lincRNA-p21 level and the markers of liver fibrosis including α-SMA and Col1A1. However, there was no correlation of serum lincRNA-p21 level with the markers of viral replication, liver inflammatory activity, and liver function. Notably, during primary HSCs culture, loss of lincRNA-p21 expression was associated with promoter methylation. Serum lincRNA-p21 could serve as a potential biomarker of liver fibrosis in CHB patients. Down-regulation of lincRNA-p21 in liver fibrosis may be associated with promoter methylation.
      PubDate: 2017-02-09T03:20:38.889312-05:
      DOI: 10.1111/jvh.12680
       
  • Hepatitis B virus reactivation in breast cancer patients undergoing
           chemotherapy: A review and meta-analysis of prophylaxis management
    • Authors: Z. Liu; L. Jiang, G. Liang, E. Song, W. Jiang, Y. Zheng, C. Gong
      Abstract: Hepatitis B virus (HBV) reactivation during or after chemotherapy in patients with breast cancer has become a remarkable clinical problem. Prophylactic nucleos(t)ide analogues (NAs) are recommended for patients with breast cancer who are hepatitis B surface antigen (HBsAg) positive before chemotherapy. We performed an up-to-date meta-analysis to compare the efficacy of prophylactic lamivudine use with nonprophylaxis in HBsAg-positive breast cancer patients undergoing chemotherapy. PubMed, the Cochrane Library and China National Knowledge Infrastructure (CNKI) databases were searched for relevant articles until June 2016. Eligible articles comparing the efficacy of prophylactic lamivudine use with nonprophylaxis in HBsAg-positive breast cancer patients undergoing chemotherapy were identified. Eight studies which had enrolled 709 HBsAg-positive breast cancer patients undergoing chemotherapy were analysed. Lamivudine prophylaxis significantly reduced the rates of chemotherapy-associated hepatitis B flares in chronic hepatitis B in breast cancer compared with patients with nonprophylaxis (odds ratio [OR]=0.15, 95% confidence interval [CI]: 0.07-0.35, P
      PubDate: 2017-02-05T22:00:28.012809-05:
      DOI: 10.1111/jvh.12672
       
  • Immune modulation by the hepatitis C virus core protein
    • Authors: C. Fernández-Ponce; M. Dominguez-Villar, J. P. Muñoz-Miranda, M. M. Arbulo-Echevarria, R. Litrán, E. Aguado, F. García-Cozar
      Abstract: Hepatitis C virus (HCV) infection is currently the most important cause of chronic viral hepatitis in the world and one of the most frequent indications for liver transplantation. HCV uses different strategies to evade the innate and adaptive immune response, and this evasion plays a key role in determining viral persistence. Several HCV viral proteins have been described as immune modulators. In this review, we will focus on the effect of HCV nucleocapsid core protein in the function of immune cells and its correlation with the findings observed in HCV chronically infected patients. Effects on immune cell function related to both extracellular and intracellular HCV core localization will be considered. This review provides an updated perspective on the mechanisms involved in HCV evasion related to one single HCV protein, which could become a key tool in the development of new antiviral strategies able to control and/or eradicate HCV infection.
      PubDate: 2017-02-02T05:35:43.5625-05:00
      DOI: 10.1111/jvh.12675
       
  • Safety and efficacy of direct-acting antivirals for the treatment of
           chronic hepatitis C in a real-world population aged 65 years and older
    • Authors: F. Conti; S. Brillanti, F. Buonfiglioli, R. Vukotic, M. C. Morelli, C. Lalanne, M. Massari, F. G. Foschi, V. Bernabucci, I. Serio, G. M. Prati, E. Negri, L. Badia, P. Caraceni, P. Muratori, G. Vitale, A. Porro, M. Morotti, G. Mazzella, P. Andreone
      Abstract: The availability of direct-acting antiviral agents (DAA) regimens has expanded the pool of patients eligible for treatment. However, data on the virologic response and tolerability of DAAs in elderly patients are lacking. We evaluated the efficacy and safety of DAAs in patients with advanced fibrosis/cirrhosis in real-life practice with the focus on those aged ≥65 years. Between January and December 2015, all consecutive patients with HCV-related advanced fibrosis/cirrhosis treated with DAA at eleven tertiary referral centres in Emilia Romagna (Italy) were enrolled. Regimen choice was based on viral genotype and stage of disease, according to guidelines. The primary end point was sustained virologic response 12 weeks after the end of treatment (SVR12). Overall, 282 of 556 (50.7%) patients evaluated were elderly, most of them with cirrhosis. Antiviral therapy was stopped prematurely in four (1.4%) patients. Two patients, both with cirrhosis, died during treatment due to worsening of liver/renal function. SVR12 was achieved by 94.7% and was comparable to that obtained in patients aged
      PubDate: 2017-02-02T05:25:45.559297-05:
      DOI: 10.1111/jvh.12663
       
  • Persistence of antibody to Hepatitis A virus 20 years after receipt of
           Hepatitis A vaccine in Alaska
    • Authors: I. D. Plumb; L. R. Bulkow, M. G. Bruce, T. W. Hennessy, J. Morris, K. Rudolph, P. Spradling, M. Snowball, B. J. McMahon
      Abstract: Hepatitis A vaccine is recommended for children ≥1 year old to prevent hepatitis A virus (HAV) infection. However, the duration of vaccine-induced immunity is unknown. We evaluated a cohort of Alaska Native persons 20 years after HAV vaccination. Children aged 3-6 years had been previously randomized to receive three doses of HAV vaccine (360 ELISA units/dose) at: (i) 0,1,2 months; (ii) 0,1,6 months; and (iii) 0,1,12 months. We measured anti-HAV antibody concentrations every 2-3 years; described geometric mean concentrations (GMC) and the proportion with protective antibody (≥20 mIU mL-1) over time; and modelled the change in GMC using fractional polynomial regression. Of the 144 participants, after 20 years 52 (36.1%) were available for the follow-up (17, 18, 17 children in Groups A, B and C, respectively). Overall, 46 (88.5%) of 52 available participants had anti-HAV antibody concentrations ≥20 mIU mL-1, and overall GMC was 107 mIU mL-1. Although GMC levels were lower in Group A (60; CI 34-104) than in Group B (110; CI 68-177) or Group C (184; CI 98-345) (B vs C: P=.168; A vs B/C: P=.011), there was no difference between groups after adjusting for peak antibody levels post-vaccination (P=.579). Models predicted geometric mean concentrations of 124 mIU mL-1 after 25 years, and 106 mIU mL-1 after 30 years. HAV vaccine provides protective antibody levels 20 years after childhood vaccination. Lower antibody levels in Group A may be explained by a lower initial peak response. Our results suggest a booster vaccine dose is unnecessary for at least 25-30 years.
      PubDate: 2017-02-02T04:36:02.448075-05:
      DOI: 10.1111/jvh.12676
       
  • Antibody-dependent and antibody-independent uptake of HBsAg across human
           leucocyte subsets is similar between individuals with chronic hepatitis B
           virus infection and healthy donors
    • Authors: H. Tharinger; I. Rebbapragada, D. Samuel, N. Novikov, M. H. Nguyen, R. Jordan, C. R. Frey, S. Pflanz
      Abstract: Maintaining detectable levels of antibodies to hepatitis B surface antigen (HBsAg) in serum after HBsAg sero-conversion is the key clinical endpoint indicative of recovery from infection with hepatitis B virus (HBV). As HBV-infected hepatocytes secrete HBsAg subviral particles in vast excess over HBV virions, detectable hepatitis B surface antibody (anti-HBs) titres imply complete elimination of HBV virions as well as HBsAg particles. Although intrahepatic phagocytes, for example Kupffer cells, are thought to mediate clearance of HBsAg via antibody (Ab)-dependent and Ab-independent mechanisms, the relative contributions of circulating phagocytic cell types to HBsAg elimination are poorly characterized. Understanding the role of various immune cell subsets in the clearance of HBsAg is important because Ab-dependent or Ab-independent phagocytic HBsAg uptake may modulate presentation of HBsAg-derived epitopes to antigen-specific T cells and hence plays a critical role in adaptive immunity against HBV. This study aims to characterize phagocytic leucocyte subsets capable of internalizing HBsAg immune complexes (HBsAg:IC) or un-complexed HBsAg particles in whole blood directly ex vivo. The data show that uptake of HBsAg:IC occurs most prominently in monocytes, B cells, dendritic cells and in neutrophils. In contrast, B cells, and to a lesser degree also monocytes, seem to be effective phagocytes for un-complexed HBsAg. Importantly, a similar pattern of phagocytic HBsAg uptake was observed in blood from chronic hepatitis B (CHB) patients compared to healthy controls, suggesting that phagocytosis-related cellular functions are not altered in the context of CHB.
      PubDate: 2017-02-01T22:15:35.222256-05:
      DOI: 10.1111/jvh.12667
       
  • Population dynamics of hepatitis C virus subtypes in injecting drug users
           on methadone maintenance treatment in China associated with economic and
           health reform
    • Authors: S. Zhou; E. Cella, W. Zhou, W.-H. Kong, M.-Q. Liu, P.-L. Liu, M. Ciccozzi, M. Salemi, X. Chen
      Abstract: The extensive genetic heterogeneity of hepatitis C virus (HCV) requires in-depth understanding of the population dynamics of different viral subtypes for more effective control of epidemic outbreaks. We analysed HCV sequences data from 125 participants in Wuhan, China. These participants were newly infected by subtype 1b (n=13), 3a (n=15), 3b (n=50) and 6a (n=39) while on methadone maintenance treatment (MMT). Bayesian phylogenies and demographic histories were inferred for these subtypes. Participants infected with HCV-1b and 3a were clustered in well-supported monophyletic clades, indicating local subepidemics. Subtypes 3b and 6a strains were intermixed with other Chinese isolates, as well as isolates from other Asian countries, reflecting ongoing across geographic boundary transmissions. Subtypes 1b and 3a declined continuously during the past ten years, consistent with the health and economic reform in China, while subtype 3b showed ongoing exponential growth and 6a was characterized by several epidemic waves, possibly related to the recently growing number of travellers between China and other Asian countries. In conclusion, results of this study suggest that HCV subtype 3b and 6a subepidemics in China are currently not under control, and new epidemic waves may emerge given the rapid increase in international travelling following substantial economic growth.
      PubDate: 2017-02-01T03:16:38.507059-05:
      DOI: 10.1111/jvh.12677
       
  • National treatment programme of hepatitis C in Egypt: Hepatitis C virus
           model of care
    • Authors: W. El-Akel; M. H. El-Sayed, M. El Kassas, M. El-Serafy, M. Khairy, K. Elsaeed, K. Kabil, M. Hassany, A. Shawky, A. Yosry, M. K. Shaker, Y. ElShazly, I. Waked, G. Esmat, W. Doss
      Abstract: Hepatitis C virus (HCV) infection is a major health problem in Egypt as the nation bears the highest prevalence rate worldwide. This necessitated establishing a novel model of care (MOC) to contain the epidemic, deliver patient care and ensure global treatment access. In this review, we describe the process of development of the Egyptian model and future strategies for sustainability. Although the magnitude of the HCV problem was known for many years, the HCV MOC only came into being in 2006 with the establishment of the National Committee for Control of Viral Hepatitis (NCCVH) to set up and implement a national control strategy for the disease and other causes of viral hepatitis. The strategy outlines best practices for patient care delivery by applying a set of service principles through identified clinical streams and patient flow continuums. The Egyptian national viral hepatitis treatment programme is considered one of the most successful and effective public health programmes. To date, more than one million patients were evaluated and more than 850 000 received treatment under the umbrella of the programme since 2006. The NCCVH has been successful in establishing a strong infrastructure for controlling viral hepatitis in Egypt. It established a nationwide network of digitally connected viral hepatitis-specialized treatment centres covering the country map to enhance treatment access. Practice guidelines suiting local circumstances were issued and regularly updated and are applied in all affiliated centres. This review illustrates the model and the successful Egyptian experience. It sets an exemplar for states, organizations and policy-makers setting up programmes for care and management of people with hepatitis C.
      PubDate: 2017-02-01T03:12:58.50618-05:0
      DOI: 10.1111/jvh.12668
       
  • Can Legislation Prohibiting Weight Discrimination Improve Psychological
           Well-Being' A Preliminary Investigation
    • Authors: Rebecca L. Pearl; Rebecca M. Puhl, John F. Dovidio
      Abstract: Weight-based discrimination is pervasive and increases vulnerability to poor mental health among targeted individuals. Legislation prohibiting weight discrimination has been proposed as an avenue for reducing social injustice. The present research examines how mere knowledge of such legislation may improve the psychological well-being of individuals who have experienced unfair treatment due to weight. In an experiment administered online, 214 adults with overweight/obesity read a vignette exemplifying weight discrimination and were randomly assigned to one of two conditions, in which they were informed that weight discrimination was illegal or legal, and then responded to questionnaires assessing internalized weight bias, affect, perceived pervasiveness of weight discrimination, and support for anti-discrimination legislation. Analysis of covariance revealed that participants with obesity in the Illegal condition exhibited lower levels of internalized weight bias than did participants in the Legal condition. Participants in the Illegal condition also exhibited less negative affect and more positive affect than did those in the Legal condition. No significant effects of condition on perceived pervasiveness of weight discrimination or legislation support emerged. Findings suggest that mere knowledge of legislation prohibiting weight discrimination has the potential to reduce weight bias internalization and improve affective responses among individuals with obesity.
      PubDate: 2017-01-25T04:30:47.402995-05:
      DOI: 10.1111/asap.12128
       
  • HCV reinfection incidence among individuals treated for recent infection
    • Authors: M. Martinello; J. Grebely, K. Petoumenos, E. Gane, M. Hellard, D. Shaw, J. Sasadeusz, T. L. Applegate, G. J. Dore, G. V. Matthews
      Abstract: One challenge to HCV elimination through therapeutic intervention is reinfection. The aim of this analysis was to calculate the incidence of HCV reinfection among both HIV-positive and HIV-negative individuals treated for recent HCV infection (estimated infection duration
      PubDate: 2017-01-23T03:20:27.517274-05:
      DOI: 10.1111/jvh.12666
       
  • Interferon-free therapies for patients with chronic hepatitis C genotype 3
           infection: A systematic review
    • Authors: V. Gimeno-Ballester; M. Buti, R. San Miguel, M. Riveiro, R. Esteban
      Abstract: Treatment of hepatitis C virus (HCV) infection with genotype 3 remains a challenge. The HCV elimination rate with direct-acting antivirals (DAAs) is lower than the values reported for other HCV genotypes. In addition, genotype 3-infected patients have a higher risk of disease progression and hepatocellular carcinoma. The aim of this study was to review the relevant literature concerning the treatment of HCV genotype 3 patients with interferon-free regimens. A literature search was conducted in the PubMed/Medline, Embase and Web of Science electronic databases. Trials enrolling patients with chronic hepatitis C infection treated with DAAs with or without ribavirin were included. Two investigators independently evaluated the trials for inclusion criteria, risk of bias and data extraction. The primary outcome was sustained virological response (SVR). In total, 323 references were identified, and 29 met the inclusion criteria: 18 general clinical trials, three general observational studies, three studies in patients with decompensated liver cirrhosis and four studies in HIV–HCV-coinfected patients. Overall, 4068 genotype 3 patients were included. As compared with sofosbuvir and ribavirin for 24 weeks, sofosbuvir/velpatasvir for 12 weeks or sofosbuvir plus daclatasvir plus ribavirin for 12 weeks provided higher SVR rates, particularly in patients with cirrhosis. Treatment of patients with decompensated cirrhosis remains a great challenge. Sofosbuvir/ledipasvir+ribavirin for 12 weeks were associated with an SVR of 85% in these patients. In summary, treatment of HCV genotype 3 patients is improving rapidly, and this population may no longer be considered a difficult-to-treat subgroup in the near future.
      PubDate: 2017-01-23T03:15:32.951372-05:
      DOI: 10.1111/jvh.12660
       
  • A systematic model improves hepatitis C virus birth cohort screening in
           hospital-based primary care
    • Authors: A. Goel; J. Sanchez, L. Paulino, C. Feuille, J. Arend, B. Shah, D. Dieterich, P. V. Perumalswami
      Abstract: Despite national and local governing board recommendations in the United States of America to perform an HCV screening test in baby boomers, screening rates remain low. Our goal was to study the impact of an HCV screening and link-to-care programme with patient navigation in two New York City primary care practices. This was a 2-year prospective study of patients born between 1945-1965 (“baby boomers”) with encounters at two primary care practices at the Mount Sinai Hospital between November 1, 2013 and November 30, 2015. Baseline HCV screening rates were collected for four months. A multifaceted intervention was sequentially implemented involving electronic alerts, housestaff education, data feedback and patient navigation. HCV screening rates and link to care, defined as attending an appointment with a viral hepatitis specialist, were compared before and after these interventions. There were 14 642 primary care baby boomer patients of which 4419 (30.2%) were newly screened during the study. There was a significant increase in HCV screening rates from 55% to 75% (P
      PubDate: 2017-01-23T02:00:23.099003-05:
      DOI: 10.1111/jvh.12669
       
  • Impact of treatment on hepatitis C virus transmission and incidence in
           Egypt: A case for treatment as prevention
    • Authors: H. H. Ayoub; L. J. Abu-Raddad
      Abstract: Egypt has launched a hepatitis C virus (HCV) treatment programme using direct-acting antivirals (DAAs). Our aim was to assess the impact of five plausible programme scale-up and sustainability scenarios for HCV treatment as prevention in Egypt. We developed and analysed a mathematical model to assess programme impact using epidemiologic, programming and health economics measures. The model was parametrized with current and representative natural history, HCV prevalence and programme data. HCV incidence in Egypt is declining, but will persist at a considerable level for decades unless controlled by interventions. Across the five programme scenarios, 1.75-5.60 million treatments were administered by 2030. Reduction in incidence (annual number of new infections) by 2030 ranged between 29% and 99%, programme-attributed reduction in incidence rate (new infections per susceptible person per year) ranged between 18% and 99%, number of infections averted ranged between 42 393 and 469 599, and chronic infection prevalence reached as low as 2.8%-0.1%. Reduction in incidence rate year by year hovered around 7%-15% in the first decade of the programme in most scenarios. Treatment coverage in 2030 ranged between 24.9% and 98.8%, and number of treatments required to avert one new infection ranged between 9.5 and 12.1. Stipulated targets for HCV by 2030 could not be achieved without scaling-up treatment to 365 000 per year and sustaining it for a decade. In conclusion, DAA scale-up will have an immense and immediate impact on HCV incidence in Egypt. Elimination by 2030 is feasible if sufficient resources are committed to programme scale-up and sustainability. HCV treatment as prevention is a potent and effective prevention approach.
      PubDate: 2017-01-23T01:50:28.750222-05:
      DOI: 10.1111/jvh.12671
       
  • Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective
           and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV)
           infection in patients with severe renal impairment: A multicentre
           experience
    • Authors: R. Muñoz-Gómez; D. Rincón, A. Ahumada, E. Hernández, M. J. Devesa, S. Izquierdo, M. Ortiz, A. Hernández-Albujar, C. Fernández-Rodríguez, M. Calvo, R. González, M. Lozano, G. Castellano, I. Fernández-Vázquez
      Abstract: Limited data are available on direct-acting antivirals for treating hepatitis C virus (HCV) infection in patients with severe renal impairment. The aim of this study was to evaluate the effectiveness and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) ± dasabuvir (DSV) ± ribavirin (RBV) in patients with stage 4 or 5 chronic kidney disease (CKD) and HCV genotype 1 or 4 infection in real clinical practice, and to investigate pharmacological interactions. This retrospective study included patients treated with OBV/PTV/r+DSV±RBV or OBV/PTV/r+RBV with CKD stage 4 (eGFR: 15-29 mL/min/1.73m2) or 5 (eGFR
      PubDate: 2017-01-20T04:35:47.721201-05:
      DOI: 10.1111/jvh.12664
       
  • More improvement than progression of liver fibrosis following
           antiretroviral therapy in a longitudinal cohort of HIV-infected patients
           with or without HBV and HCV co-infections
    • Authors: Y. Ding; S. Duan, R. Ye, Y. Yang, S. Yao, J. Wang, D. Cao, X. Liu, L. Lu, M. Jia, Z. Wu, N. He
      Abstract: We examined the effect of combination antiretroviral therapy (cART) on liver fibrosis among HIV-infected patients with or without hepatitis B (HBV) or C virus (HCV) co-infection. This was a retrospective cohort study of HIV-infected patients receiving cART during 2004-2016. Liver fibrosis was assessed using Fibrosis-4 (FIB-4) score with three classifications: Class 1, 3.25. Of 3900 participants, 68.6% were HIV mono-infected, 5.3% were HIV/HBV co-infected, 23.8% were HIV/HCV co-infected and 2.3% were HIV/HBV/HCV co-infected. Participants received follow-up treatment (median was 3.3 years). Improvement to a lower class was observed in Class 2 (52.6%) and Class 3 (74.2%), respectively. Progression to a higher class was observed in 12.8% and 5.0% in Class 1 and Class 2, respectively, and with a median time of 5.7 months. For improvement to lower classes, older age, male, Dai ethnicity, injection drug use, HCV co-infection and tenofovir for treatment were negative predictors, but in Class 3 of FIB-4 and time-updated increases in CD4 count from baseline were positive predictors. For progression to higher classes, older age, male, Jingpo ethnicity and HCV co-infection were positive predictors, while baseline CD4 count and in Class 2 of FIB-4 were negative predictors. Improvement to lower class linked with decreased mortality risk among patients in Class 3. Early cART initiation for HIV-infected patients with and without hepatitis co-infections may mitigate or slow down some of liver fibrosis, but special attention should be given to those who are older, male, co-infected with HCV.
      PubDate: 2017-01-20T00:11:17.472834-05:
      DOI: 10.1111/jvh.12658
       
  • U.S. Children's Stereotypes and Prejudicial Attitudes toward Arab Muslims
    • Authors: Christia Spears Brown; Hadeel Ali, Ellen A. Stone, Jennifer A. Jewell
      Abstract: The current study examined whether children in elementary school in the United States held stereotypes and prejudicial attitudes about Arab Muslims relative to other groups. Children (n = 136), ages 6–11 (55 boys, 81 girls), were read three counterbalanced vignettes about different immigrant families who moved to the United States: one family from the Middle East with clothing markers indicating they are Muslim (e.g., hijab), one family from the Middle East without clothing markers indicating religion, and one White family from Ireland. Children's responses indicated stereotypes associating the Arab Muslim male target as more anti-American and hostile and the Arab Muslim female target as more oppressed than others, both consistent with prevalent media stereotypes. Children's positive and negative affective intergroup attitudes were also measured, along with their attitudes about who can be an “American,” with children showing both a positivity and negativity bias against Arab Muslims. Children who had some contact with Muslims or were familiar with Islam felt more positively toward Arab Muslims than less informed children. In addition, if children perceived Arab Muslims to be prototypical “Americans,” and identified as very American themselves, they also held positive attitudes toward Arab Muslims. Implications for prejudice reduction interventions are discussed.
      PubDate: 2017-01-18T00:40:23.22869-05:0
      DOI: 10.1111/asap.12129
       
  • Differences in background characteristics of patients with chronic
           hepatitis C who achieved sustained virologic response with interferon-free
           versus interferon-based therapy and the risk of developing hepatocellular
           carcinoma after eradication of hepatitis C virus in Japan
    • Authors: H. Toyoda; T. Tada, K. Takaguchi, T. Senoh, N. Shimada, A. Hiraoka, K. Michitaka, T. Ishikawa, T. Kumada
      Abstract: We compared the background characteristics of patients with chronic hepatitis C who achieved eradication of hepatitis C virus (HCV), that is sustained virologic response (SVR), with interferon (IFN)-based versus IFN-free antiviral therapy in Japan. In addition, we used a previously reported risk assessment model to compare the incidence of hepatocellular carcinoma (HCC) after SVR by treatment type. Pretreatment characteristics of 1533 patients who achieved SVR with IFN-based therapy and 1086 patients with IFN-free therapy from five institutions across Japan were compared. The risk of HCC after SVR was assessed based on pretreatment characteristics, and the incidence of HCC after SVR was estimated in both groups. Age and serum alpha-fetoprotein levels were higher, platelet count was lower, and liver fibrosis was more advanced in patients who achieved SVR with IFN-free therapy compared with IFN-based therapy. The incidence of HCC after SVR in the IFN-free group was estimated to be more than twofold higher than in the IFN-based therapy group (7.29% vs. 3.09%, and 6.23% vs. 3.01% when excluding patients who have underwent curative treatment for HCC). There are large differences in pretreatment characteristics between patients who achieved SVR with IFN-based and IFN-free therapies in Japan, which are associated with differential risk of HCC after SVR. These differences can influence the incidence of HCC after SVR and should be taken into consideration when comparing IFN-based and IFN-free therapies in terms of hepatocarcinogenesis suppression with HCV eradication.
      PubDate: 2017-01-11T03:45:22.794038-05:
      DOI: 10.1111/jvh.12665
       
  • Issue Information
    • Pages: 177 - 179
      PubDate: 2017-01-27T03:01:40.752602-05:
      DOI: 10.1111/jvh.12589
       
  • NS5A inhibitors for the treatment of hepatitis C infection
    • Authors: Stefano Gitto; Nesrine Gamal, Pietro Andreone
      Pages: 180 - 186
      Abstract: Today, we are witnessing a new era for the treatment of hepatitis C with excellent rates of virologic response and very good safety profiles. Among the many classes of direct-acting antivirals, the inhibitors of nonstructural protein 5A are particularly interesting. NS5A is a phosphorylated protein with a relevant role in viral replication. HCV-NS5A inhibitors show high potency, very good safety profile and high barrier to resistance. The amazing in vitro effectiveness of this class is associated with great efficacy in clinical trials in combination protocols with antivirals of other classes, with sustained virological response (SVR) obtained in more than 90% of patients. Herein, we sought to review the current knowledge regarding the NS5A protease complex inhibitors with special emphasis on clinical efficacy and development of viral resistance.
      PubDate: 2017-01-20T00:26:08.428766-05:
      DOI: 10.1111/jvh.12657
       
  • Hepatitis C infection and other drug-related harms among inpatients who
           injected drugs in Turkey
    • Authors: A. Alaei; K. Alaei, K. Waye, M. Tracy, M. Nalbandyan, E. Mutlu, M. K. Cetin
      Abstract: Hepatitis C virus (HCV) is easily spread among those who share drug injection equipment. Due to the ease of contraction and growing prevalence of HCV in Eastern Europe, the aims of this study focused on describing risky injection practices as well as the prevalence of HCV, HIV and hepatitis B virus (HBV) among people who inject drugs (PWID) who were admitted to public and private drug treatment centres in Turkey from 2012 to 2013. Other aims included identifying correlates of needle sharing and HCV infection. Of the 4694 inpatients who ever injected drugs and the 3914 who injected in the past 30 days, nearly all (98%) reported heroin as their drug of choice, the vast majority reported ever sharing a needle (73.4% and 79.3%), and the mean age at first injection was 23 years. Of current PWID, 51.9% were HCV-positive, 5.9% were HBV-positive and only 0.34% of lifetime PWID were HIV-positive. Predictors of increased needle sharing include younger age, being unemployed, having lesser education and reporting heroin as a drug of choice. Significant predictors of HCV infection included being 40 years or older, receiving treatment in the Mediterranean region of Turkey, reporting heroin as a primary substance, a longer duration of drug use and sharing needles. With this information, it is essential to improve access to clean injection equipment in Turkey, to focus on improving education on clean injection practices and to enhance efforts in testing and treating HCV-positive PWID.
      PubDate: 2016-12-28T01:05:27.689713-05:
      DOI: 10.1111/jvh.12662
       
  • Sacralizing Liberals and Fair-Minded Conservatives: Ideological Symmetry
           in the Moral Motives in the Culture War
    • Authors: Jeremy A. Frimer; Caitlin E. Tell, Matt Motyl
      Abstract: Political arguments may endure seemingly into perpetuity because the conflicted combatants view the issues in different ways, with one side decrying unfairness and the other side decrying attacks on the sacrosanct. We tested whether both conservatives and liberals rely on protecting the sacrosanct when justifying their attitudes on some contentious moral issues. In four studies, we examine how liberals and conservatives justify their political attitudes on the issues of same-sex marriage and the Keystone XL oil pipeline. Liberals supported same-sex marriage rights primarily in the name of fairness and equality; conservatives primarily opposed same-sex marriage rights as a matter of protecting the sanctity of traditional marriage. Symmetrically, liberals primarily opposed the development of the Keystone XL oil pipeline as a matter of protecting the sanctity of the Earth; conservatives supported the development of the pipeline as a matter of promoting fairness (e.g., corporate rights; as well as citing economic and foreign policy implications). Like conservatives, liberals also bring sacred thinking to moral issues. The culture war is mired in stalemate partly because each side considers some matters to be sacrosanct, and other matters as suitable for revision in the name of fairness.
      PubDate: 2016-12-27T08:40:52.210835-05:
      DOI: 10.1111/asap.12127
       
  • Epigenetic analysis of the IFNλ3 gene identifies a novel marker for
           response to therapy in HCV-infected subjects
    • Authors: J. F. Waring; J. W. Davis, E. Dumas, D. Cohen, K. Idler, S. Abel, R. Georgantas, T. Podsadecki, S. Dutta
      Abstract: Chronic hepatitis C virus (HCV) infection is characterized by high interindividual variability in response to pegylated interferon and ribavirin. A genetic polymorphism on chromosome 19 (rs12979860) upstream of interferon-λ3 (IFNλ3) is associated with a twofold change in sustained virologic response rate after 48 weeks of treatment with pegylated interferon/ribavirin in HCV genotype 1 (GT1) treatment-naïve patients. We conducted epigenetic analysis on the IFNλ3 promoter to investigate whether DNA methylation is associated with response to HCV therapy. DNA samples from HCV GT1-infected subjects receiving an interferon-free paritaprevir-containing combination regimen (N=540) and from HCV-uninfected, healthy controls (N=124) were analysed for IFNλ3 methylation levels. Methylation was strongly associated with rs12979860 allele status whether adjusting for HCV status (r=65.0%, 95% CI: [60.2%, 69.5%]), or not (r=64.4%), both with P
      PubDate: 2016-12-20T03:35:34.193248-05:
      DOI: 10.1111/jvh.12661
       
  • Hepatitis C viraemia reversibly maintains subset of antigen-specific
           T-bet+ tissue-like memory B cells
    • Authors: L.-Y. Chang; Y. Li, D. E. Kaplan
      Abstract: Background: Chronic antigen exposure and/or ageing increases the frequency of T-box expressed in T cells (T-bet)-expressing B-lymphocytes in mice. The frequency and significance of B-cell T-bet expression during chronic hepatitis C (HCV) infection in human subjects has never been described. Methods: Healthy controls, cirrhotic and noncirrhotic HCV-infected patients, and non-HCV patients with cirrhosis were recruited. Peripheral blood mononuclear cells were phenotyped for expression of T-bet and related markers by flow cytometry. In a subset of patients who underwent antiviral therapy and were cured of HCV infection (sustained virological response), the dynamics of T-bet expression in B cells was monitored. After cure, convalescent B cells were tested for T-bet expression after re-exposure to infected plasma or recombinant HCV proteins. Results: Forty-nine patients including 11 healthy donors, 30 hepatitis C-infected individuals (nine with liver cancer, 13 with cirrhosis, eight without cirrhosis) and eight patients with cirrhosis due to non-HCV-related cause were recruited. We found that B cells in patients with chronic HCV exhibited increased frequency of T-bet+ B cells relative to noninfected individuals (median 11.5% v. 2.2%, P
      PubDate: 2016-12-20T03:15:25.738827-05:
      DOI: 10.1111/jvh.12659
       
  • Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and
           treatment-experienced patients with hepatitis C virus genotype 1
           infection and chronic kidney disease in the United States
    • Authors: E. Elbasha; W. Greaves, D. Roth, C. Nwankwo
      Abstract: Among patients with chronic kidney disease (CKD) in the United States, HCV infection causes significant morbidity and mortality and results in substantial healthcare costs. A once-daily oral regimen of elbasvir/grazoprevir (EBR/GZR) for 12 weeks was found to be a safe and efficacious treatment for HCV in patients with CKD. We evaluated the cost-effectiveness of EBR/GZR in treatment-naïve and treatment-experienced CKD patients compared with no treatment (NoTx) and pegylated interferon plus ribavirin (peg-IFN/RBV) using a computer-based model of the natural history of chronic HCV genotype 1 infection, CKD and liver disease. Data on baseline characteristics of the simulated patients were obtained from NHANES, 2000–2010. Model inputs were estimated from published studies. Cost of treatment with EBR/GZR and peg-INF/RBV were based on wholesale acquisition cost. All costs were from a third-party payer perspective and were expressed in 2015 U.S. dollars. We estimated lifetime incidence of liver-related complications, liver transplantation, kidney transplantation, end-stage live disease mortality and end-stage renal disease mortality; lifetime quality-adjusted life years (QALY); and incremental cost-utility ratios (ICUR). The model predicted that EBR/GZR will significantly reduce the incidence of liver-related complications and prolong life in patients with chronic HCV genotype 1 infection and CKD compared with NoTx or use of peg-IFN/RBV. EBR/GZR-based regimens resulted in higher average remaining QALYs and higher costs (11.5716, $191 242) compared with NoTx (8.9199, $156 236) or peg-INF/RBV (10.2857, $186 701). Peg-IFN/RBV is not cost-effective, and the ICUR of EBR/GZR compared with NoTx was $13 200/QALY. Treatment of a patient on haemodialysis with EBR/GZR resulted in a higher ICUR ($217 000/QALY). Assuming a threshold of $100 000 per QALY gained for cost-effectiveness, use of elbasvir/grazoprevir to treat an average patient with CKD can be considered cost-effective in the United States.
      PubDate: 2016-12-13T22:31:26.851109-05:
      DOI: 10.1111/jvh.12639
       
  • HBV/HCV co-infection is associated with a high level of HCV spontaneous
           clearance among drug users and blood donors in China
    • Authors: H. Xiong; X. Rong, M. Wang, R. Xu, K. Huang, Q. Liao, J. Huang, J. Chen, C. Li, X. Tang, Z. Shan, M. Zhang, K. Nelson, Y. Fu
      Abstract: Understanding the biology of spontaneous clearance of hepatitis C virus (HCV) infection could lead to improved strategies to prevent the sequelae associated with chronic HCV infection. Chronic infections with hepatitis virus are very common in China, but the factors associated with spontaneous clearance of HCV have not been adequately studied. We evaluated the spontaneous clearance of HCV among 1918 drug users and 1526 HCV-seropositive blood donors in Guangzhou, China. Among participants who were co-infected with hepatitis B virus (HBV), 41.38% of drug users and 39.47% of blood donors had cleared their HCV infection without antiviral therapy compared to 9.41% of drug users and 16.73% of blood donors who were mono-infected with a single virus (P
      PubDate: 2016-12-12T00:30:27.609668-05:
      DOI: 10.1111/jvh.12644
       
  • Time to viral suppression is not related to achievement of SVR12 in HCV
           GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and
           dasabuvir with or without ribavirin
    • Authors: S. Alqahtani; R. Ozaras, V. Isakov, D. Wyles, P. Ferenci, J. J. Feld, F. Calinas, M. Gschwantler, E. Gane, D. Crawford, I. M. Jacobson, E. O. Dumas, M. King, M. Sulkowski
      Abstract: High rates of sustained virologic response at post-treatment week 12 (SVR12) were achieved in six phase 3 trials of ombitasvir (OBV, an NS5A inhibitor), paritaprevir (an NS3/4A protease inhibitor) co-dosed with ritonavir (PTV/r) + dasabuvir (DSV, an NS5B RNA polymerase inhibitor) (ie, 3D regimen) with or without ribavirin (RBV) in adults with chronic genotype (GT) 1 hepatitis C virus (HCV) infection. We assessed whether time to first HCV RNA value below the lower limit of quantification in patients with and without cirrhosis was associated with achievement of SVR12. Data were analysed from GT1-infected patients enrolled in six phase 3 studies of 3D ± RBV. Patients who experienced non-virologic failure were excluded from analysis. HCV RNA was determined using the Roche COBAS TaqMan RT-PCR assay (lower limit of quantification, LLOQ =25 IU/mL). SVR12 was analysed by week of first HCV RNA suppression, defined as HCV RNA
      PubDate: 2016-12-09T07:25:41.167604-05:
      DOI: 10.1111/jvh.12641
       
  • Effectiveness and safety of sofosbuvir-based regimens plus an NS5A
           inhibitor for patients with HCV genotype 3 infection and cirrhosis.
           Results of a multicenter real-life cohort
    • Authors: S. Alonso; M. Riveiro-Barciela, I. Fernandez, D. Rincón, Y. Real, S. Llerena, F. Gea, A. Olveira, C. Fernandez-Carrillo, B. Polo, J. A. Carrión, A. Gómez, M. J. Devesa, C. Baliellas, Á. Castro, J. Ampuero, R. Granados, J. M. Pascasio, A. Rubín, J. Salmeron, E. Badia, J. M. M. Planas, S. Lens, J. Turnes, J. L. Montero, M. Buti, R. Esteban, C. M. Fernández-Rodríguez
      Abstract: Patients with HCV genotype 3 (GT3) infection and cirrhosis are currently the most difficult to cure. We report our experience with sofosbuvir+daclatasvir (SOF+DCV) or sofosbuvir/ledipasvir (SOF/LDV), with or without ribavirin (RBV) in clinical practice in this population. This was a multicenter observational study including cirrhotic patients infected by HCV GT3, treated with sofosbuvir plus an NS5A inhibitor (May 2014-October 2015). In total, 208 patients were included: 98 (47%) treatment-experienced, 42 (20%) decompensated and 55 (27%) MELD score >10. In 131 (63%), treatment was SOF+DCV and in 77 (37%), SOF/LDV. Overall, 86% received RBV. RBV addition and extension to 24 weeks was higher in the SOF/LDV group (95% vs 80%, P=.002 and 83% vs 72%, P=.044, respectively). A higher percentage of decompensated patients were treated with DCV than LDV (25% vs 12%, P=.013). Overall, SVR12 was 93.8% (195/208): 94% with SOF+DCV and 93.5% with SOF/LDV. SVR12 was achieved in 90.5% of decompensated patients. Eleven treatment failures: 10 relapses and one breakthrough. RBV addition did not improve SVR (RR: 1.08; P=.919). The single factor associated with failure to achieve SVR was platelet count
      PubDate: 2016-12-09T07:24:21.104427-05:
      DOI: 10.1111/jvh.12648
       
  • Sofosbuvir plus ribavirin in treatment-naïve patients with chronic
           hepatitis C virus genotype 1 or 3 infection in India
    • Authors: S. R. Shah; A. Chowdhury, R. Mehta, D. Kapoor, A. Duseja, A. Koshy, A. Shukla, A. Sood, K. Madan, R. Sud, S. Nijhawan, R. Pawan, M. Prasad, K. Kersey, D. Jiang, E. Svarovskaia, B. Doehle, B. Kanwar, M. Subramanian, S. K. Acharya, S. Sarin
      Abstract: Until 2014, pegylated interferon plus ribavirin was the recommended standard of care for the treatment of chronic hepatitis C virus (HCV) infection in India. This open-label phase 3b study, conducted across 14 sites in India between 31 March 2014 and 30 November 2015, evaluated the efficacy and safety of sofosbuvir plus ribavirin therapy among treatment-naïve patients with chronic genotype 1 or 3 HCV infection. A total of 117 patients with genotype 1 or 3 HCV infection were randomized 1:1 to receive sofosbuvir 400 mg and weight-based ribavirin (1000 or 1200 mg) daily for 16 or 24 weeks. Among those with genotype 1 infection, the primary efficacy endpoint of sustained virologic response at 12 weeks post-treatment (SVR12) was reported in 90% (95% confidence intervals [CI], 73-98) and 96% (95% CI, 82-100) of patients following 16 and 24 weeks of treatment, respectively. For patients with genotype 3 infection, SVR12 rates were 100% (95% CI, 88-100) and 93% (95% CI, 78-99) after 16 and 24 weeks of therapy, respectively. Adverse events, most of which were mild or moderate in severity, occurred in 69% and 57% of patients receiving 16 and 24 weeks of treatment, respectively. The most common treatment-emergent adverse events were asthenia, headache and cough. Only one patient in the 24-week group discontinued treatment with sofosbuvir during this study. Overall, sofosbuvir plus ribavirin therapy achieved SVR12 rates ≥90% and was well tolerated among treatment-naïve patients with chronic genotype 1 or 3 HCV infection in India.
      PubDate: 2016-12-09T01:25:26.999793-05:
      DOI: 10.1111/jvh.12654
       
  • Outcome of hepatitis B and C virus-associated hepatocellular carcinoma
           occurring after renal transplantation
    • Authors: N. Kanaan; C. Raggi, E. Goffin, M. De Meyer, M. Mourad, M. Jadoul, C. Beguin, B. Kabamba, I. Borbath, Y. Pirson, Z. Hassoun
      Abstract: Kidney transplant recipients (KTR) are subjected to immunosuppressive therapy that can enhance hepatitis B and C virus replication, leading to cirrhosis and hepatocellular carcinoma (HCC). The aim of this study was to assess the prevalence and outcome of HCC in KTR. Case-control study. Patients with chronic HBV and/or HCV infection who underwent kidney transplantation between 1976 and 2011 and subsequently developed HCC were compared to a control group of patients with chronic HBV and/or HCV infection, matched for gender and age at HCC diagnosis, who did not receive kidney transplantation. Among 2944 KTR, 330 had hepatitis B and/or C. Fourteen developed HCC, a period prevalence of 4.2%. Age at HCC diagnosis was 52.6 ± 6.5 years (53.5 ± 5.7 in controls, P=.76). Time between transplantation and HCC diagnosis was 16.7 ± 2.7 years. Six HCCs were related to HBV, six to HCV and two to co-infection with HBV and HCV. Immunosuppressive therapy was comparable in HBV, HCV and HBV+HCV patients. At diagnosis, 71% of patients met Milan criteria (65% in the control group, P=.4). Alpha-fetoprotein levels, tumour characteristics and treatment modalities were comparable between both groups. Patient survival 2 years after HCC diagnosis was 28% in KTR, compared to 68% in controls (P=.024). Survival after HCC diagnosis is significantly worse in KTR compared to nontransplanted patients with HBV and/or HCV. Prevention is crucial and should be based on viral eradication/suppression before or after transplantation.
      PubDate: 2016-12-05T01:47:03.115711-05:
      DOI: 10.1111/jvh.12655
       
  • Determination of hepatitis B phenotype using biochemical
           and serological markers
    • Authors: A. M. Di Bisceglie; M. Lombardero, J. Teckman, L. Roberts, H. L. A. Janssen, S. H. Belle, J. H. Hoofnagle,
      Abstract: The aim of this study was to assess the validity of categorization of chronic hepatitis B viral infection into stages or phases based upon measures of disease activity and viral load, assuming these phenotypes will be useful for prognostication and determining the need for antiviral therapy. We assessed the phenotype of hepatitis B of 1,390 adult participants enrolled in the Hepatitis B Research Network Cohort Study, using a computer algorithm. Only 4% were immune tolerant, while 35% had chronic hepatitis B (18% e antigen positive and 17% e antigen negative) while 23% were inactive carriers. Strikingly, 38% of participants did not fit clearly into any one of these groups and were considered indeterminant. The largest subset of indeterminants had elevated serum aminotransferases with low levels of HBV DNA (less than 10,000 iu/mL). Subsequent determination of hepatitis B phenotype on the next available laboratory tests showed that 64% remained indeterminant. These findings call into question the validity of conventional staging of hepatitis B, in large part because of the substantial proportion of patients who do not fit readily into one of the usual stages or phases. Further studies are needed of the indeterminant category of chronic hepatitis B viral infection, including assessments of whether patients in this group are perhaps in transition to another phase or if they are a distinct phenotype with a need to assess liver disease severity and need for antiviral therapy. (ClinicalTrials.gov identifier NCT01263587).
      PubDate: 2016-12-05T01:40:42.712-05:00
      DOI: 10.1111/jvh.12643
       
  • Racial disparity in all-cause mortality among hepatitis C virus-infected
           individuals in a general US population, NHANES III
    • Authors: B. Emmanuel; M. D. Shardell, L. Tracy, S. Kottilil, S. S. El-Kamary
      Abstract: There are few long-term nationally representative studies of all-cause mortality among those infected with hepatitis C virus (HCV). When an additional 5 years of data were made publicly available in 2015, the Third National Health and Nutrition Examination Survey Linked Mortality File became the longest nationally representative study in the United States. Our objective was to update the estimated HCV-associated all-cause mortality in the general US population and determine any differences by sex, age and race/ethnicity. HCV status was assessed in 9117 nationally representative adults aged 18-59 years from 1988 to 1994, and mortality follow-up of the same individuals was completed through 2011 and made publicly available in 2015. There were 930 deaths over a median follow-up of 19.8 years. After adjusting for all covariate risk factors, chronic HCV had 2.63 times (95% CI: 1.59-4.37; P=.0002) higher all-cause mortality rate ratio (MRR) compared with being HCV negative. All-cause MRR was stratified by sex, age and race/ethnicity. Only race/ethnicity was a significant effect modifier of MRR (P
      PubDate: 2016-12-01T01:03:12.418318-05:
      DOI: 10.1111/jvh.12656
       
  • The association between hepatitis B self-awareness and depression:
           Exploring the modifying effects of socio-economic factors
    • Authors: Y. Liu; K. Tang, J. Long, C. Zhao
      Abstract: China has a high prevalence of HBV. Despite previous studies, uncertainty remains about the association of HBV with depression. This study explores the strength of the association and the modifying effects of participants' self-awareness of the disease and their socio-economic status. Data from the baseline of a Chinese cohort study of approximately 500 000 adults were analysed. Depression was assessed using the Composite International Diagnostic Inventory. Blood spot tests were conducted to detect hepatitis B surface antigen. Logistic regression was used to assess the association between depression and HBV adjusting for demographic, socio-economic and lifestyle factors of major depression. To understand the effect modifications of disease self-awareness and socio-economic factors, a series of stratified analyses were undertaken. The overall prevalence of HBV is 3.2%, with 2.8% screen-detected and 0.3% self-reported cases. There was an 84% increased odds of depression among self-reported HBV patients (OR=1.84, 95% CI: 1.16-2.90), but no association was found in the screen-detected group (OR=0.98, 95% CI: 0.79-1.23). Male (OR=2.28, 95% CI: 1.30-3.98), younger age (OR=3.57, 95% CI: 1.82-7.00), rural resident (OR=2.31, 95% CI: 1.36-3.94), lower household income (OR=2.38, 95% CI: 1.34-4.25) and agricultural worker (OR=2.92, 95% CI: 1.63-5.77) were found having greater odds of depression in the HBV self-aware group, compared to those without HBV. A strong association between hepatitis B self-awareness and depression was found. Lower socio-economic status could modify the association between hepatitis B status and depression. Further studies are needed to understand the underlying psychosocial mechanisms of the association.
      PubDate: 2016-11-28T02:56:49.506941-05:
      DOI: 10.1111/jvh.12647
       
  • Protective efficacy and hepatitis B virus clearance in mice enhanced by
           cell-mediated immunity with novel prime-boost regimens
    • Authors: X. Chuai; P. Chen, H. Chen, W. Wang, Y. Deng, L. Ruan, W. Li, W. Tan
      Abstract: In this study, anti-hepatitis B virus (HBV) immunity was evaluated in mice using several regimens of the HBV recombinant protein vaccine HBSS1 that expressed in CHO cells containing S (1-223 aa) and preS1 (21-47 aa) and recombinant adenovirus rAdSS1 vaccine. Further, the protective efficacy of these vaccine regimens was studied in a mouse model. High titres of antigen-specific antibodies and neutralizing activity were elicited in mice after vaccination. However, robust multi-antigen (preS1 and S)-specific cell-mediated immunity (CMI) was only detected in mice primed with HBSS1 and boosted with rAdSS1. Moreover, functional T-cell responses with high levels of cytokines and antigen-specific cytotoxic T-cell responses (CD107a+CD8+) were also detected in the mice. Rapid clearance of hepatitis B surface antigen and HBV DNA in blood and significantly decreased hepatitis B envelope antigen levels were observed in mice immunized with the heterogeneous prime-boost vaccine after hepatitis B virus challenge by hydrodynamic injection (HI) of pCS-HBV1.3. The clearance of HBV correlated well with antigen-specific CMI (Th1 and CTL responses) and cytokine profiles (IFN-γ, TNF-α, IL-2) elicited by vaccination. Taken together, our results might contribute to the development of new human HBV vaccines and a better understanding of the mechanisms underlying immune protection and clearance of hepatitis B virus infection.
      PubDate: 2016-11-25T04:45:55.205277-05:
      DOI: 10.1111/jvh.12649
       
  • Prognosis of 1169 hepatitis C chronically infected patients with
           decompensated cirrhosis in the predirect-acting antiviral era
    • Authors: S. A. McDonald; H. A. Innes, E. Aspinall, P. C. Hayes, M. Alavi, H. Valerio, D. J. Goldberg, S. J. Hutchinson
      Abstract: At a population level, little is known regarding the risk of liver- and nonliver-related mortality and hospitalization and the development of hepatocellular carcinoma (HCC) in hepatitis C virus (HCV)-infected patients with decompensated cirrhosis (DC). This large-scale national record-linkage study estimates these outcomes following first hospital admission for DC. Record-linkages between national HCV diagnosis and clinical databases and the national inpatient hospital episode database and mortality register were conducted to follow-up the disease course of all identified HCV-diagnosed and chronically infected persons. The study population consisted of 1169 HCV chronically infected persons who had a first hospital admission for DC within the period 1994-2013. We observed an overall average annual percentage change of 12.6% in new DC patients (from 63 in 1994-1999 to 541 in 2009-2013), with no evidence for any improvement in the relative risks of liver-related or all-cause death over time. Between 1 January 1994 and 31 May 2014, 722 and 95 DC patients had died of a liver- and a nonliver-related cause, respectively, and 106 patients had a subsequent first admission for HCC. The 5-year cumulative incidence of liver-related mortality, nonliver-related mortality and first subsequent HCC admission was 61.3%, 8.2% and 8.8%, respectively. The health burden in HCV-infected patients associated with development of decompensated cirrhosis has increased dramatically over the last 20 years. Our findings establish the baseline mortality and HCC progression rates in DC patients against which the impact of new antiviral therapies can be measured.
      PubDate: 2016-11-25T04:45:39.686941-05:
      DOI: 10.1111/jvh.12646
       
  • Role of primary T-cell immunodeficiency and hepatitis B coinfection on
           spontaneous clearance of hepatitis C: The BC Hepatitis Testers Cohort
    • Authors: N. Islam; M. Krajden, M. Gilbert, P. Gustafson, A. Yu, M. Kuo, M. Chong, M. Alvarez, J. Wong, M. W. Tyndall, N. Z. Janjua
      Abstract: T-cell host immune response against hepatitis C virus (HCV) has been suggested to play an important role in determining HCV infection outcome. However, data from human studies are not available. This study examined the effect of primary T-cell deficiency along with other factors on the spontaneous clearance of HCV in a large population-based cohort in British Columbia, Canada. The BC Hepatitis Testers Cohort includes all individuals tested for HCV in BC in 1990-2013 linked with data on their medical visits, hospitalizations and prescription drugs. HCV-positive individuals with at least one valid HCV PCR test on/after HCV diagnosis (n=46 783) were included in this study. To examine factors associated with the spontaneous clearance of HCV, multivariable logistic regression was fitted on the full sample, and Cox proportional hazards model on the HCV seroconverters. Spontaneous clearance was observed in 25.1% (n=11 737) of those tested for HCV. After adjusting for potential confounders, the odds of spontaneous clearance of HCV was lower in people with primary T-cell immunodeficiency (adjusted odds ratio [aOR]: 0.55, 95% CI: 0.32-0.94), and higher in females (aOR: 1.61, 95% CI: 1.54-1.68) and in those coinfected with HBV (aOR: 2.31, 95% CI: 1.93-2.77). Similar results were observed in HCV seroconverters except HBV coinfection was not significant. In conclusion, primary T-cell immunodeficiency is associated with a lower spontaneous clearance of HCV while female sex and coinfection with HBV are associated with a higher spontaneous clearance.
      PubDate: 2016-11-25T00:30:27.711064-05:
      DOI: 10.1111/jvh.12650
       
  • A molecular transmission network of recent hepatitis C infection in people
           with and without HIV: Implications for targeted treatment strategies
    • Authors: S. R. Bartlett; J. O. Wertheim, R. A. Bull, G. V. Matthews, F. M. J. Lamoury, K. Scheffler, M. Hellard, L. Maher, G. J. Dore, A. R. Lloyd, T. L. Applegate, J. Grebely
      Abstract: Combining phylogenetic and network methodologies has the potential to better inform targeted interventions to prevent and treat infectious diseases. This study reconstructed a molecular transmission network for people with recent hepatitis C virus (HCV) infection and modelled the impact of targeting directly acting antiviral (DAA) treatment for HCV in the network. Participants were selected from three Australian studies of recent HCV from 2004 to 2014. HCV sequence data (Core-E2) from participants at the time of recent HCV detection were analysed to infer a network by connecting pairs of sequences whose divergence was ≤.03 substitutions/site. Logistic regression was used to identify factors associated with connectivity. Impact of targeting HCV DAAs at both HIV co-infected and random nodes was simulated (1 million replicates). Among 236 participants, 21% (n=49) were connected in the network. HCV/HIV co-infected participants (47%) were more likely to be connected compared to HCV mono-infected participants (16%) (OR 4.56; 95% CI; 2.13-9.74). Simulations targeting DAA HCV treatment to HCV/HIV co-infected individuals prevented 2.5 times more onward infections than providing DAAs to randomly selected individuals. Results demonstrate that genetic distance-based network analyses can be used to identify characteristics associated with HCV transmission, informing targeted prevention and treatment strategies.
      PubDate: 2016-11-24T02:00:22.653956-05:
      DOI: 10.1111/jvh.12652
       
  • Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus-infected
           patients with decompensated liver disease
    • Authors: E. Lawitz; F. Poordad, J. A. Gutierrez, T. N. Kakuda, G. Picchio, G. Beets, A. Vandevoorde, P. Van Remoortere, B. Jacquemyn, D. Luo, S. Ouwerkerk-Mahadevan, L. Vijgen, V. Van Eygen, M. Beumont
      Abstract: Approximately three million individuals in the United States are chronically infected with hepatitis C virus (HCV). Chronic HCV infection may lead to the development of compensated as well as decompensated liver cirrhosis. The Phase II IMPACT study was conducted in HCV genotype 1- or 4-infected cirrhotic patients with portal hypertension or decompensated liver disease and assessed for the first time the combination of the three direct-acting antivirals simeprevir, daclatasvir and sofosbuvir. Treatment-naïve or treatment-experienced adults with Child-Pugh (CP) score
      PubDate: 2016-11-23T01:25:24.763155-05:
      DOI: 10.1111/jvh.12645
       
  • Cultural Differences in the Role of Economic Competitiveness in Prejudice
           toward Immigrants and Foreign Workers
    • Authors: Hyeyoung Shin; John F. Dovidio
      Abstract: This study investigated cultural differences in the role of economic competitiveness in prejudice toward immigrants and foreign workers between Northern European-heritage and East Asian cultures. Because economic competitiveness and achievement are associated with core cultural values in Northern European-heritage cultures, we hypothesized that economic competitiveness would be associated with prejudice toward immigrants and foreign workers more strongly in Northern European-heritage than in East Asian cultures. Results based on nationally representative samples drawn from the World Values Survey revealed that prejudice toward immigrants and foreign workers was generally higher in East Asian (South Korea and China) than in Northern European-heritage (Norway and the United States) cultures. However, as predicted, a stronger association was found between economic competitiveness and prejudice toward immigrants and foreign workers in Northern European-heritage than East Asian cultures, controlling for sociodemographic backgrounds of participants (gender, age, education, and income), ecological diversity of each country, values of uniqueness and conformity, attitude toward ethnic diversity, and racism. These findings support the hypothesis that the central values of a culture shape the nature of prejudice within it, including prejudice toward immigrants and foreign workers, and highlight the importance of understanding the cultural dynamics of prejudice.
      PubDate: 2016-10-21T02:25:23.950562-05:
      DOI: 10.1111/asap.12124
       
  • Issue Information - ASAP Reviewers
    • Pages: 1 - 1
      PubDate: 2016-12-27T06:11:53.033423-05:
      DOI: 10.1111/asap.12083
       
  • Issue Information - Editorial Board
    • Pages: 2 - 2
      PubDate: 2016-12-27T06:11:53.249143-05:
      DOI: 10.1111/asap.12084
       
  • Issue Information - TOC
    • Pages: 3 - 5
      PubDate: 2016-12-27T06:11:57.632455-05:
      DOI: 10.1111/asap.12082
       
  • Stereotype Content Model, Causal Models, and Allegations of Age
           Discrimination: Should the Law Change'
    • Authors: Katlyn S. Farnum; Richard L. Wiener
      Pages: 100 - 124
      Abstract: In 2009, the Supreme Court decided, in Gross v. FBL, that the law governing age discrimination should be interpreted in a stricter manner than before. After Gross, age discrimination claims are tried under but for causality in which the plaintiff's age must be the direct cause of the adverse action, as opposed to mixed motive causality allowable under Title VII, in which age would only have to be a motivating factor. Previous research has shown that but for instructions lead to more pro-defendant verdicts, regardless of case strength, as compared to mixed motive instructions. This study reports on a simulated jury experiment that sought to uncover the influence of stereotypes concerning older workers on juror verdicts in an age discrimination case. Older worker stereotypes were assessed using the Stereotype Content Model's warmth and competence dimensions. In line with previous research, participants were more likely to find for the defendant under but for instructions, as compared to mixed motive. Further, mock jurors’ stereotypes predicted their verdicts, but only under the but for instructions, suggesting that jurors rely on stereotypes when they are limited in the case facts they can consider. Implications for policy changes and future research directions are discussed.
      PubDate: 2016-05-02T05:18:16.085611-05:
      DOI: 10.1111/asap.12112
       
  • The Relationship between Weight-Based Prejudice and Attitudes towards
           Obesity-Reducing Public Policies
    • Authors: Michael B. Berg; Linda Lin, Sara M. Hollar, Samantha N. Walker, Lauren E. Erickson
      Pages: 125 - 142
      Abstract: A variety of public policies have been proposed to counteract obesity. Many factors, such as the desire to promote better health, may affect the support for such policies. However, given the pervasiveness of weight-based prejudice in the United States, it is likely that antifat bias may influence policy attitudes as well. We predicted that higher levels of weight-based prejudice would be positively associated with attitudes towards obesity-reducing policies and would be associated specifically with support for policies that are more punitive in nature. In two separate studies, participants were surveyed about their level of support for various public health polices and their explicit antifat prejudice attitudes, along with other relevant attitudinal and demographic information. Study 1 established that weight-based prejudice was significantly associated with support for more punitive policies even when controlling for other related factors. Study 2 extended this result to show that the link between antifat attitudes and support for punitive policies was foremost about targeting overweight individuals as opposed to targeting unhealthy behavior. These findings highlight the need for thoughtful consideration of how best to separate out the prejudicial motive to punish from the need to promote health when choosing, garnering support for, and implementing obesity-related policies.
      PubDate: 2016-05-05T01:50:29.758304-05:
      DOI: 10.1111/asap.12113
       
  • Do You See What I See' The Consequences of Objectification in Work
           Settings for Experiencers and Third Party Predictors
    • Authors: Sarah J. Gervais; Richard L. Wiener, Jill Allen, Katlyn S. Farnum, Katherine Kimble
      Pages: 143 - 174
      Abstract: Sexual objectification is a significant problem that permeates all areas of women's lives including the workplace. This research examines the impact of sexual objectification on women in work settings by integrating objectification, sexual harassment, and affective forecasting theories. We used a laboratory analogue that included undergraduate women who actually experienced objectification during a work interview (i.e., experiencers) and third-party predictors (including female and male undergraduates as well as female and male community workers) who anticipated the effects of objectification (i.e., predictors). We measured actual and anticipated emotions, performance, and sexual harassment following objectification. We found that both mild and severe objectification caused weaker positive affect, stronger negative affect, worse work performance, and higher sexual harassment judgments, but these effects were primarily driven by predictors anticipating worse outcomes following objectification compared to what experiencers actually reported. We also found that experiencers’ responses to objectification were moderated by benevolent sexism with women lower in benevolent sexism responding more similarly to predictors relative to women higher in benevolent sexism. Both experiencers and predictors evaluated interviewers who engaged in objectification equally negatively. Finally, we explored differences between predictors who were female and male undergraduate students versus community workers and found that these parties anticipated different consequences, depending on worker status and gender. Implications for sexual objectification, sexual harassment, and affective forecasting theories as well as practical implications for policy and law are discussed.
      PubDate: 2016-05-25T00:35:30.756441-05:
      DOI: 10.1111/asap.12118
       
  • Goal Framing in Public Issue and Action Decisions
    • Authors: Katherine D. Arbuthnott; Andrea Scerbe
      Pages: 175 - 192
      Abstract: Loss aversion is observed both in psychological research and life: Individuals will work harder to avoid losing something than to gain the same thing. Most previous research examining the impact of gain versus loss framing has used personal economic or health decisions, such as preferred investments or health treatments. The present study examined whether goal framing also influences decisions about public resources such as economic development and environmental protection. After reading descriptions of the gains or losses associated with one of these issues, participants rated their concern and support for public actions related to several economic, environmental, and social actions. Results indicated loss aversion: Ratings were higher when losses associated with failing to adopt development or protection programs were emphasized. Thus, decision biases associated with goal framing may apply to decisions about public as well as personal resources. The implications of these findings for policy and communications professions are discussed.
      PubDate: 2016-06-03T04:51:17.332696-05:
      DOI: 10.1111/asap.12119
       
  • Chronic hepatitis C infection and liver disease in HIV-coinfected patients
           in Asia
    • Authors: N. Durier; E. Yunihastuti, K. Ruxrungtham, N. V. Kinh, A. Kamarulzaman, D. Boettiger, A. Widhani, A. Avihingsanon, B. V. Huy, S. F. B. Syed Omar, A. Sanityoso, S. Chittmittrapap, N. T. H. Dung, V. Pillai, T. Suwan-Ampai, M. Law, A. H. Sohn, G. Matthews
      Pages: 187 - 196
      Abstract: Data on markers of hepatitis C virus (HCV) disease in HIV-HCV-coinfected patients in resource-limited settings are scarce. We assessed HCV RNA, HCV genotype (GT), IL28B GT and liver fibrosis (FibroScan®) in 480 HIV-infected patients with positive HCV antibody in four HIV treatment centres in South-East Asia. We enrolled 165 (34.4%) patients in Jakarta, 158 (32.9%) in Bangkok, 110 (22.9%) in Hanoi and 47 (9.8%) in Kuala Lumpur. Overall, 426 (88.8%) were male, the median (IQR) age was 38.1 (34.7-42.5) years, 365 (76.0%) reported HCV exposure through injecting drug use, and 453 (94.4%) were on combination antiretroviral therapy. The median (IQR) CD4 count was 446 (325-614) cells/mm3 and 208 (94.1%) of 221 patients tested had HIV-1 RNA
      PubDate: 2016-12-05T01:27:24.913069-05:
      DOI: 10.1111/jvh.12630
       
  • Polyculturalism among Undergraduates at Diverse Universities: Associations
           through Intergroup Anxiety with Academic and Alcohol Outcomes
    • Authors: Lisa Rosenthal; Sheri R. Levy, Bonita London, Melissa A. Lewis
      Pages: 193 - 226
      Abstract: U.S. universities are increasingly racially/ethnically diverse. Simultaneously, undergraduate graduation rates and alcohol use remain important concerns. Understanding factors that contribute to success and well-being among students in these diverse college settings is critical to informing educational policy and programming. Polyculturalism is the belief that different racial/ethnic groups have always interacted, exchanged, and influenced each other, and it has been associated with more positive intergroup attitudes and greater comfort with diversity. Across four studies (three cross-sectional, one longitudinal) with racially/ethnically diverse undergraduates at two diverse institutions in the Northeastern United States, controlling for potentially confounding variables (year in college, age, race/ethnicity, nativity, high school GPA, current GPA, endorsement of multiculturalism and colorblindness, self-esteem, ethnic identification, general social anxiety, and mood across time points), greater endorsement of polyculturalism was associated with greater academic self-efficacy, greater sense of belonging, less use of alcohol to cope with intergroup anxiety, and fewer adverse alcohol-related consequences; further, lower intergroup anxiety mediated those associations. Results suggest studying polyculturalism and intergroup anxiety may contribute to our understanding of undergraduate outcomes at diverse institutions. Future work might explore how educational policy and programming can incorporate polyculturalism to promote engagement and well-being of undergraduates at these diverse institutions.
      PubDate: 2016-06-17T03:16:20.306128-05:
      DOI: 10.1111/asap.12121
       
  • Prevention of allograft HCV recurrence with peri-transplant human
           monoclonal antibody MBL-HCV1 combined with a single oral direct-acting
           antiviral: A proof-of-concept study
    • Authors: H. L. Smith; R. T. Chung, P. Mantry, W. Chapman, M. P. Curry, T. D. Schiano, E. Boucher, P. Cheslock, Y. Wang, D. C. Molrine
      Pages: 197 - 206
      Abstract: Patients with active hepatitis C virus (HCV) infection at transplantation experience rapid allograft infection, increased risk of graft failure and accelerated fibrosis. MBL-HCV1, a neutralizing human monoclonal antibody (mAb) targeting the HCV envelope, was combined with a licensed oral direct-acting antiviral (DAA) to prevent HCV recurrence post-transplant in an open-label exploratory efficacy trial. Eight subjects received MBL-HCV1 beginning on the day of transplant with telaprevir initiated between days 3 and 7 post-transplantation. Following FDA approval of sofosbuvir, two subjects received MBL-HCV1 starting on the day of transplant with sofosbuvir initiated on day 3. Combination treatment was administered for 8-12 weeks or until the stopping rule for viral rebound was met. The primary endpoint was undetectable HCV RNA at day 56 with exploratory endpoints of sustained virologic response (SVR) at 12 and 24 weeks post-treatment. Both subjects receiving mAb and sofosbuvir achieved SVR24. Four of eight subjects in the mAb and telaprevir group met the primary endpoint; one subject achieved SVR24 and three subjects relapsed 2-12 weeks post-treatment. The other four subjects experienced viral breakthrough. There were no serious adverse events related to study treatment. This proof-of-concept study demonstrates that peri-transplant immunoprophylaxis combined with a single oral direct-acting antiviral in the immediate post-transplant period can prevent HCV recurrence.
      PubDate: 2016-11-07T03:40:40.333498-05:
      DOI: 10.1111/jvh.12632
       
  • Multidisciplinary managed care networks—Life-saving interventions
           for hepatitis C patients
    • Authors: J. M. Tait; H. Wang, B. P. Stephens, M. Miller, P. G. McIntyre, S. Cleary, J. F. Dillon
      Pages: 207 - 215
      Abstract: Successful hepatitis C virus (HCV) therapy depends on effective pathways of care. Over two decades, we have developed four sequential models of care latterly using a multidisciplinary managed care network to improve HCV testing, care and treatment. This was a cohort study to evaluate the effectiveness of care pathways, carried out using all HCV antibody-positive individuals tested in a geographical region between 1994 and 2014. The study involved 3122 HCV-positive patients. They were divided into four subgroups representing different care pathways defined by their date of HCV antibody diagnosis. The number who accessed treatment services within 1 year of diagnosis increased from 77 of 292 (26.3%) to 521 of 821 (72.9%). The rate of treatment starts within 1 year of diagnosis increased from 6 of 292 (2.0%) to 133 of 821 (16.2%), and the sustained viral response rate improved from 61.6% to 77.4%. All-cause mortality decreased from 232 of 688 (33.7%) in subgroup A to 55 of 1207 (4.5%) in subgroup D, and multivariate analysis showed that pathway type was an independent predictor of mortality irrespective of age, sex, SVR status or HIV co-infection with pathway in D having an odds ratio of 0.53(0.40-0.77; P
      PubDate: 2016-11-07T03:06:08.503611-05:
      DOI: 10.1111/jvh.12633
       
  • Functional connectivity alterations in patients with chronic hepatitis C
           virus infection: A multimodal MRI study
    • Authors: S. Kharabian Masouleh; S. Herzig, L. Klose, E. Roggenhofer, H. Tenckhoff, T. Kaiser, A. Thöne-Otto, M. Wiese, T. Berg, M. L. Schroeter, D. S. Margulies, A. Villringer
      Pages: 216 - 225
      Abstract: Chronic hepatitis C virus (HCV) infection is associated with fatigue and depression. Cognitive impairments are also reported in a smaller number of HCV-positive patients. Recent studies linked HCV to low-grade inflammation in brain. Here, we test the hypothesis that chronic HCV is associated with 3T-neuroimaging-derived grey matter volume (GMV) and functional connectivity alterations in a sample of chronic HCV (1b), without severe liver disease. Regional GMV and resting-state fMRI-derived eigenvector centrality (EC) were compared between 19 HCV-positive patients and 23 healthy controls (all females, 50-69 and 52-64 years, respectively), controlling for white matter hyperintensities and age. Standard tests were used to assess fatigue, depression and cognitive performance. Also, liver fibrosis stage and viral load were quantified among patients. In comparison with controls, HCV-positive patients had higher scores in fatigue and depression, and worse alertness scores. The groups performed similarly in other cognitive domains. We report higher EC in a cluster in the right anterior superior parietal lobule in patients, while no differences are found in GMV. Post hoc functional connectivity analysis showed increased connectivity of this cluster with primary and secondary somatosensory cortex, and temporal and occipital lobes in patients. Higher mean EC in the superior parietal cluster, adjusted for mean framewise displacement, was associated with better memory and attention performance, but not with fatigue, depression, viral load or level of liver fibrosis, among patients. These results suggest a compensatory mechanism in chronic hepatitis C and explain equivocal results in the literature about cognitive deficits in infected persons. Further studies should define the relation of these connectivity changes to the brain's inflammatory activity.
      PubDate: 2016-11-04T00:31:32.007745-05:
      DOI: 10.1111/jvh.12634
       
  • Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ±
           dasabuvir ± ribavirin: An early access programme for Spanish patients
           with genotype 1/4 chronic hepatitis C virus infection
    • Authors: C. Perelló; J. A. Carrión, B. Ruiz-Antorán, J. Crespo, J. Turnes, J. Llaneras, S. Lens, M. Delgado, J. García-Samaniego, F. García-Paredes, I. Fernández, R. M. Morillas, D. Rincón, J. C. Porres, M. Prieto, M. Lázaro Ríos, C. Fernández-Rodríguez, J. A. Hermo, M. Rodríguez, J. I. Herrero, P. Ruiz, J. R. Fernández, M. Macías, J. M. Pascasio, J. M. Moreno, M. Á. Serra, J. Arenas, Y. Real, F. Jorquera, J. L. Calleja,
      Pages: 226 - 237
      Abstract: Over the last 5 years, therapies for hepatitis C virus (HCV) infection have improved significantly, achieving sustained virologic response (SVR) rates of up to 100% in clinical trials in patients with HCV genotype 1. We investigated the effectiveness and safety of ombitasvir/paritaprevir/ritonavir±dasabuvir in an early access programme. This was a retrospective, multicentre, national study that included 291 treatment-naïve and treatment-experienced patients with genotype 1 or 4 HCV infection. Most patients (65.3%) were male, and the mean age was 57.5 years. The mean baseline viral load was 6.1 log, 69.8% had HCV 1b genotype, 72.9% had cirrhosis and 34.7% were treatment-naïve. SVR at 12 weeks posttreatment was 96.2%. Four patients had virological failure (1.4%), one leading to discontinuation. There were no statistical differences in virological response according to genotype or liver fibrosis. Thirty patients experienced serious adverse events (SAEs) (10.3%), leading to discontinuation in six cases. Hepatic decompensation was observed in five patients. Four patients died during treatment or follow-up, three of them directly related to liver failure. Multivariate analyses showed a decreased probability of achieving SVR associated with baseline albumin, bilirubin and Child-Pugh score B, and a greater probability of developing SAEs related to age and albumin. This combined therapy was highly effective in clinical practice with an acceptable safety profile and low rates of treatment discontinuation.
      PubDate: 2016-12-15T02:15:23.212911-05:
      DOI: 10.1111/jvh.12637
       
  • Stereotypes of Sex Offenders’ Romantic Partners Predict Intent to
           Discriminate
    • Authors: Tyler J. Plogher; Margaret C. Stevenson, Evan W. McCracken
      Pages: 227 - 260
      Abstract: Registered sex offenders’ family members perceive themselves to be the direct targets of public scrutiny, ostracism, harassment, and employment discrimination. Study 1 offers a preliminary exploration of the stereotypes of registered sex offenders’ romantic partners. Participants’ open-ended responses were coded and subjected to inter-rater reliability, using a coding scheme that was both exploratory in nature, while also informed by theory and research. Partially supporting our hypotheses, participants primarily perceived sex offenders’ romantic partners as fearful, vulnerable, deviant, and mentally ill, but also as good, forgiving people who want to help reform the offender. In Study 2, we developed an attitudes toward sex offenders’ partners scale, designed to measure participants’ endorsement of stereotypes about offenders’ partners. As predicted, endorsement of negative stereotypes about offenders’ romantic partners (i.e., that they are deviant and predatory, as well as fearful and vulnerable) predicted greater support for sex offender legislation and less support for hiring offenders’ partners across a variety of employment contexts. Moreover, political conservatives were more likely than liberals to discriminate against offenders’ partners in job hiring contexts—an effect statistically explained by conservatives’ endorsement of negative stereotypes about offenders’ partners.
      PubDate: 2016-11-03T05:46:01.340986-05:
      DOI: 10.1111/asap.12126
       
  • Usefulness of albumin-bilirubin grade for evaluation of long-term
           prognosis for hepatitis B-related cirrhosis
    • Authors: R.-C. Chen; Y.-J. Cai, J.-M. Wu, X.-D. Wang, M. Song, Y.-Q. Wang, M.-H. Zheng, Y.-P. Chen, Z. Lin, K. Q. Shi
      Pages: 238 - 245
      Abstract: Long-term prognosis varies widely among patients with hepatitis B virus (HBV)-related liver cirrhosis. Our study aimed to investigate the applicability of albumin-bilirubin (ALBI), Child-Pugh and model for end-stage liver disease (MELD) scores to the long-term prognosis prediction of HBV-related cirrhosis. Patients diagnosed with HBV-associated cirrhosis from the First Affiliated Hospital of Wenzhou Medical University between January 2010 and December 2015 were enrolled in this study. The patients were followed up every 3 months. The prognostic performance of ALBI in long-term outcome prediction for HBV-related cirrhosis was compared with Child-Pugh and MELD scores using time-dependent receiver operating characteristic curve (tdROC) and decision curve analysis. A total of 806 patients were included in our study with 275 (34.1%) deceased during the follow-up. Multivariate Cox regression analysis showed that ALBI grade was an independent predictor associated with mortality. The tdROC analysis showed that ALBI score (0.787, 0.830 and 0.833) was superior to MELD (0.693, P=.003; 0.717, P
      PubDate: 2016-11-14T01:40:23.159852-05:
      DOI: 10.1111/jvh.12638
       
  • Lamivudine therapy during the second vs the third trimester for preventing
           transmission of chronic hepatitis B
    • Authors: C. Q. Pan; W. Yi, M. Liu, G. Wan, Y.-H. Hu, M.-F. Zhou
      Pages: 246 - 252
      Abstract: There are little data on the timing of initiating lamivudine therapy for preventing transmission of hepatitis B in highly viremic mothers. Between May 2008 and January 2015, we retrospectively enrolled mothers with HBV DNA >6 log10 copies/mL who received lamivudine during pregnancy, and we compared them to untreated mothers. The primary measurement was the vertical transmission rate. The secondary outcomes were the mothers’ and infants’ safety. Among 249 consecutive mothers enrolled, 66 and 94 received lamivudine during the second and third trimesters, respectively, and 89 were untreated. At delivery, maternal mean HBV DNA levels were significantly lower in mothers who received lamivudine (4.45 log10; vs 7.16 log10 copies/mL; P
      PubDate: 2016-12-26T20:55:21.798679-05:
      DOI: 10.1111/jvh.12640
       
  • Hepatitis B infection is associated with an increased incidence of
           thrombocytopenia in healthy adults without cirrhosis
    • Authors: E.-J. Joo; Y. Chang, J.-S. Yeom, Y.-G. Lee, S. Ryu
      Pages: 253 - 258
      Abstract: The association between HBV infection and incident thrombocytopenia among subjects without cirrhosis or splenomegaly is unknown. Therefore, we sought to elucidate the association between HBV infection and the development of thrombocytopenia in a large cohort of apparently healthy men and women. A cohort study was performed in 122 200 participants without liver cirrhosis or splenomegaly who underwent comprehensive health examinations and were followed until December 2014. HBV infection was defined by the presence of hepatitis B surface antigen (HBsAg) at baseline. Thrombocytopenia was defined as a platelet count
      PubDate: 2016-11-18T05:00:21.04182-05:0
      DOI: 10.1111/jvh.12642
       
  • Socialism or Psychology: Society at the Crossroads
    • Authors: Michael Arfken
      Pages: 278 - 280
      Abstract: In a recent article, Bernice Lott suggests that modern psychology has failed to investigate in any systematic fashion existing beliefs and attitudes surrounding socialism. While there is much to commend in Lott's analysis, her support for a social democratic version of socialism tends to obscure the more revolutionary potentials of socialist practice. To adequately address social and environmental justice, I argue that the trajectory of psychological research and practice must be brought into alignment with a socialism that is committed to interrogating and ultimately destabilizing the capitalist mode of production.
      PubDate: 2016-03-11T03:16:52.923064-05:
      DOI: 10.1111/asap.12106
       
  • Making Sense of Class: A Commentary on Lott
    • Authors: Lucas A. Keefer; Chris Goode
      Pages: 281 - 284
      Abstract: While Lott's commentary rightly calls for greater attention to the consequences of capitalism, we offer further discussion of one important issue: the psychological study of social class. This work has predominantly focused on the psychological consequences of class itself by studying the ways that objective and subjective status differences influence thought and behavior. We call for a broader approach that further acknowledges the psychology of class perceptions and beliefs, one means of legitimizing (or challenging) inequality under capitalism. The role of class beliefs as a justification of, or challenge to, the status quo presents an important area for future research. (100/100)
      PubDate: 2016-05-19T02:40:47.054903-05:
      DOI: 10.1111/asap.12114
       
  • Support for Socialist Policies: The Ideological Logic of Everyday
           Practices
    • Authors: Ella Ben Hagai; Eileen L. Zurbriggen
      Pages: 285 - 289
      Abstract: To better understand why individuals come to support economic policies that increase inequalities, we suggest a more expansive understanding of ideology. A broad understanding of ideology predicts that daily engagement with the material world will produce certain narratives about the self and the obstacles faced by people. We review studies on child-rearing practices and social psychological studies on diverging understandings of the self that highlight the contrasting narratives of working and middle class people. We argue that these different narratives play a role in explaining why individuals come to support certain economic policies. This more expansive understanding of the concept of ideology can help researchers trace the links between material conditions, ideological narratives, and support for socialist or capitalist economic policies, heeding Lott's (2015) call for a structural analysis.
      PubDate: 2016-05-12T00:20:24.011063-05:
      DOI: 10.1111/asap.12117
       
  • Holocaust as the Prototype of Genocide. On Some Problems with the Modern
           State Crime Paradigm
    • Authors: Michal Bilewicz
      Pages: 321 - 324
      Abstract: The Holocaust plays a prominent role in Americans’ representation of genocide. Mazur and Vollhardt (2015) show that for this population, the prototypical genocide is a systematic large-scale racist killing, perpetrated by the modern state as part of war. Seeking the roots of such representations, this article reviews philosophical, historical, psychological, and sociological writings that put the modernization, civilization, authoritarianism, and state at the center of their theorizing about genocide. Such a “modern state crime” paradigm can lead to biased views of the nature of genocide, as well as of the psychological factors responsible for its occurrence.
      PubDate: 2016-05-05T01:50:33.498633-05:
      DOI: 10.1111/asap.12116
       
  • Beyond “Simple” Recategorization: A Commentary on Moss and
           Vollhardt
    • Authors: Laurent Licata
      Pages: 360 - 362
      Abstract: This commentary on Moss and Vollhardt's (2016) article examines how their findings complement a study by Kanazayire, Licata, Mélotte, Dusingizemungu, and Azzi (2014), which also sought to assess the effectiveness of the Rwandan government's ethnic identity policy for improving reconciliation sentiments in postgenocide Rwanda.
      PubDate: 2016-05-12T00:20:28.605335-05:
      DOI: 10.1111/asap.12115
       
  • Decolonizing Empowerment: Implications for Sustainable Well-Being
    • Authors: Tuğçe Kurtiş; Glenn Adams, Sara Estrada-Villalta
      Pages: 387 - 391
      Abstract: Dutt, Grabe, and Castro's (2015) research on implications of market participation for Maasai women's empowerment provides an important basis for rethinking liberatory standards of psychological science and international gender development. Drawing upon their research, we apply a decolonial feminist psychology analysis to the topic of empowerment. This perspective suggests that neoliberal interventions to promote empowerment and well-being in Majority-World spaces (i) may cause harm by depriving people of environmentally afforded connection and (ii) reproduce historical and ongoing forms of (neo)colonial domination in ways that are inconsistent with the broader empowerment of humanity in general.
      PubDate: 2016-06-16T02:00:49.945793-05:
      DOI: 10.1111/asap.12120
       
  • Toward a Comprehensive Understanding of the Factors Underlying Multiracial
           Person Perception
    • Authors: Jacqueline M. Chen; Jasmine B. Norman
      Pages: 417 - 420
      Abstract: Young and colleagues’ recent article substantially contributes to the understanding of multiracial perception generally and in the context of affirmative action. Their introduction of socioeconomic status as a relevant factor in the perception of Latino-White biracials highlights our need for additional research identifying which target characteristics and perceiver motives influence the perception of multiracials and under what conditions these relationships occur. We outline how future research can incorporate and expand on Young et al.’s work to better understand multiracial person perception and specify the most appropriate contexts in which these findings could be applied by practitioners.
      PubDate: 2016-06-14T21:10:25.716218-05:
      DOI: 10.1111/asap.12122
       
  • “Hearing they do not hear”: Comment on Anderson, Bushman, Donnerstein,
           Hummer, and Warburton
    • Authors: C. Glenn Cupit
      Pages: 421 - 424
      Abstract: The SPSSI summary of research into media-related violence is one of a series of such expert reviews over many years drawing much the same conclusions. It is necessary because of issues among legislators and regulators, and sections of the academic community that lead to a lack of effective policy response to the findings. The influence of media research deniers justifies the regular production of such reviews so that, should the sociopolitical climate shift, there will be a body of knowledge upon which to build a strategy for change. As such, this summary represents a valuable contribution to the field.
      PubDate: 2016-04-25T00:30:48.271996-05:
      DOI: 10.1111/asap.12109
       
  • Violence in Context: Embracing an Ecological Approach to Violent Media
           Exposure
    • Authors: Erin Glackin; Sarah A. O. Gray
      Pages: 425 - 428
      Abstract: This commentary expands on Anderson, Bushman, Donnerstein, Hummer, and Warburton's agenda for minimizing the impacts of violent media exposure (VME) on youth aggression. We argue that, in order to effectively intervene in the development of aggression and other maladaptive traits, researchers and policy-makers should take an ecological, developmental psychopathology approach to understanding children's exposure to VME within developmental, relational, environmental, and cultural contexts. Such a framework holds the most promise for identifying at-risk groups, establishing targets of intervention, and testing mechanisms of change.
      PubDate: 2016-03-14T21:20:36.981225-05:
      DOI: 10.1111/asap.12108
       
  • The Evolution of Scientific Skepticism in the Media Violence
           “Debate”
    • Authors: Douglas A. Gentile
      Pages: 429 - 434
      Abstract: After 60 years of research on media violence and aggression, the scientifically skeptical positions have evolved. This article examines some of the reasons why this issue continues to be a difficult one, and argues that, after examining the preponderance of data, the interesting skeptical questions are: (1) How can we put the pieces of the puzzle back together, given humans’ inherent complexity' (2) How do differing perspectives affect the interpretation of the data' Questions such as these may help to move past the polarizing rhetoric that has characterized much of the recent debate.
      PubDate: 2016-03-14T07:50:18.690488-05:
      DOI: 10.1111/asap.12110
       
  • Media Violence Research Needs to Look Ahead, Not Back: Commentary on
           Anderson, Bushman, Donnerstein, Hummer, and Warburton (2015)
    • Authors: Mario Gollwitzer
      Pages: 435 - 438
      Abstract: Given that media violence is still a heated debate (and that “motivated science reception” is likely to occur in such debates), reviews like the present one are very helpful. One noteworthy aspect of the present review is that it looks ahead and suggests useful pathways for parents, policy-makers, and the media industry. In all of these pathways, researchers play a key role. Media researchers should now focus on the wealth of research questions that the evolution of (violent and nonviolent) media, especially video games, has opened up.
      PubDate: 2016-03-14T07:48:55.225379-05:
      DOI: 10.1111/asap.12111
       
  • Violent Media Effects on Aggression: A Commentary from a Cross-Cultural
           Perspective
    • Authors: Barbara Krahé
      Pages: 439 - 442
      Abstract: It is argued that, despite differences in cultural norms and practices, the evidence for a link between violent media use and aggression is remarkably consistent across different countries. Along with evidence that different operationalizations of violent media use also converge across countries, these findings strengthen the conclusion that violent media are a risk factor for aggression and validate the psychological explanations for these effects. However, we need comparative studies based on a consistent methodology and a theory-based selection of cultural difference variables to properly examine the potential impact of culture on the association between violent media use and aggression.
      PubDate: 2016-03-11T03:16:35.701321-05:
      DOI: 10.1111/asap.12107
       
  • Reply to Comments on SPSSI Research Summary on Media Violence by Cupit
           (2016), Gentile (2016), Glackin and Gray (2016), Gollwitzer (2016), and
           Krahé (2016)
    • Authors: Brad J. Bushman; Craig A. Anderson, Edward Donnerstein, Tom A. Hummer, Wayne A. Warburton
      Pages: 443 - 450
      Abstract: In responding to the published comments on our SPSSI Research Summary on Media Violence, we note that several key themes emerge. In assessing the media violence research evidence, it is more informative and less biased to draw conclusions based on the full range of findings than to emphasize findings from individual studies. Using the full range of studies, it is clear that consuming violent media influences the way people think and feel, and increases the likelihood of aggressive behavior. However, when placing such findings into real world settings, it is important to consider media violence exposure as one of many risk factors for violence and aggression rather than as a sole factor. This acknowledgment of multiple causal factors does not make media violence unimportant––it is one of the few risk factors for aggression that can be addressed relatively easily and inexpensively. To this end, researchers are encouraged to now focus their efforts on finding those factors that moderate the media violence exposure–aggression link, and policy makers and professionals who work with children are encouraged to incorporate media violence science into their practices and decision-making.
      PubDate: 2016-06-29T04:52:14.361408-05:
      DOI: 10.1111/asap.12123
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
Home (Search)
Subjects A-Z
Publishers A-Z
Customise
APIs
Your IP address: 54.162.168.187
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2016